
(
  (S
    (NP
      (NP (NN Down-regulation))
      (PP (IN of)
        (NP
          (NP (NN interferon) (JJ regulatory) (NN factor) (CD 4))
          (NN gene) (NN expression)))
      (PP (IN in)
        (NP (JJ leukemic) (NNS cells)))
      (PP (IN due) (TO to)
        (NP
          (NP (NN hypermethylation))
          (PP (IN of)
            (NP (NN CpG) (NNS motifs)))
          (PP (IN in)
            (NP (DT the) (NN promoter) (NN region))))))))

(
  (S
    (NP (NN Abstract))))

(
  (S
    (S
      (SBAR (IN Although)
        (S
          (NP (DT the) (NN bcr-abl) (NN translocation))
          (VP (VBZ has)
            (VP (VBN been)
              (VP (VBN shown)
                (S
                  (VP (TO to)
                    (VP (VB be)
                      (NP
                        (NP (DT the) (JJ causative) (JJ genetic) (NN aberration))
                        (PP (IN in)
                          (NP
                            (NP (JJ chronic) (JJ myeloid) (NN leukemia))
                            (PRN (-LRB- -LRB-)
                              (NP (NN CML))
                              (-RRB- -RRB-)))))))))))))
      (, ,)
      (NP (EX there))
      (VP (VBZ is)
        (NP (JJ mounting) (NN evidence)
          (SBAR (IN that)
            (S
              (NP
                (NP (DT the) (NN deregulation))
                (PP (IN of)
                  (NP
                    (NP (JJ other) (NNS genes))
                    (, ,)
                    (PP (JJ such) (IN as)
                      (NP
                        (NP (DT the) (NN transcription) (NN factor) (NN interferon) (JJ regulatory) (NN factor) (CD 4))
                        (PRN (-LRB- -LRB-)
                          (NP (NN IRF-4))
                          (-RRB- -RRB-))))
                    (, ,))))
              (VP (VBZ is)
                (ADVP (RB also))
                (VP (VBN implicated)
                  (PP (IN in)
                    (NP
                      (NP (DT the) (NN pathogenesis))
                      (PP (IN of)
                        (NP (NN CML))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP
          (NP (NN Promoter) (NN methylation))
          (PP (IN of)
            (NP (NN CpG) (NN target) (NNS sites))))
        (CC or)
        (NP
          (NP (JJ direct) (NNS deletions/insertions))
          (PP (IN of)
            (NP (NNS genes)))))
      (VP (VBP are)
        (NP
          (NP (NNS mechanisms))
          (PP (IN of)
            (NP
              (NP (DT a)
                (ADJP
                  (ADJP (JJ reversible))
                  (CC or)
                  (ADJP (JJ permanent)))
                (NN silencing))
              (PP (IN of)
                (NP (NN gene) (NN expression))))))
        (, ,)
        (ADVP (RB respectively))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Therefore))
      (, ,)
      (NP (PRP we))
      (VP (VBD investigated)
        (SBAR (IN whether)
          (S
            (NP
              (NP (NN IRF-4) (NN promoter) (NN methylation))
              (CC or)
              (NP (NN mutation)))
            (VP (MD may)
              (VP (VB be)
                (VP (VBN involved)
                  (PP (IN in)
                    (NP
                      (NP (DT the) (NN regulation))
                      (PP (IN of)
                        (NP
                          (NP (NN IRF-4) (NN expression))
                          (PP (IN in)
                            (NP (NN leukemia) (NNS cells))))))))))))))
    (. .)))

(
  (S
    (S
      (SBAR (IN Whereas)
        (S
          (NP
            (NP (NN promoter) (NNS mutations))
            (CC or)
            (NP (JJ structural) (NNS rearrangements)))
          (VP (MD could)
            (VP (VB be)
              (VP (VBN excluded)
                (PP (IN as)
                  (NP
                    (NP (DT a) (NN cause))
                    (PP (IN of)
                      (NP
                        (NP (JJ altered) (NN IRF-4) (NN expression))
                        (PP (IN in)
                          (NP (JJ hematopoietic) (NNS cells))))))))))))
      (, ,)
      (NP (DT the) (NN IRF-4) (NN promoter) (NN methylation) (NN status))
      (VP (VBD was)
        (VP (VBN found)
          (S
            (VP (TO to)
              (ADVP (RB significantly))
              (VP (VB influence)
                (NP (NN IRF-4) (NN transcription))))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB First))
      (, ,)
      (NP
        (NP (NN treatment))
        (PP (IN of)
          (NP (JJ IRF-4-negative)
            (ADJP
              (ADJP (JJ lymphoid))
              (, ,)
              (ADJP (JJ myeloid))
              (CC and)
              (ADJP (JJ monocytic)))
            (NN cell) (NNS lines)))
        (PP (IN with)
          (NP (DT the) (JJ methylation-inhibitor) (NN 5-aza-2-deoxycytidine))))
      (VP (VBD resulted)
        (PP (IN in)
          (NP
            (NP (DT a)
              (ADJP
                (ADJP (NN time-))
                (CC and)
                (ADJP (JJ concentration-dependent)))
              (NN increase))
            (PP (IN of)
              (NP
                (NP (NN IRF-4) (NN mRNA))
                (CC and)
                (NP (NN protein) (NNS levels))))))))
    (. .)))

(
  (S
    (ADVP (RB Second))
    (, ,)
    (S
      (VP (VBG using)
        (NP (DT a)
          (ADJP
            (ADJP (JJ restriction-PCR-assay))
            (CC and)
            (ADJP (JJ bisulfite-sequencing))))))
    (NP (PRP we))
    (VP (VBD identified)
      (NP
        (ADJP (RB specifically) (VBN methylated))
        (NN CpG) (NNS sites))
      (PP
        (PP (IN in)
          (NP (NN IRF-4-negative)))
        (CC but)
        (PP (RB not) (IN in)
          (NP (JJ IRF-4-positive) (NNS cells)))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Third))
      (, ,)
      (NP (PRP we))
      (ADVP (RB clearly))
      (VP
        (VP (VBD determined)
          (NP (NN promoter) (NN methylation))
          (PP (IN as)
            (NP
              (NP (DT a) (NN mechanism))
              (PP (IN for)
                (NP
                  (NP (NN IRF-4) (NN down-regulation))
                  (PP (IN via)
                    (NP (NN reporter) (NN gene) (NNS assays))))))))
        (, ,)
        (CC but)
        (VP (VBD did) (RB not)
          (VP (VB detect)
            (NP
              (NP (DT an) (NN association))
              (PP (IN of)
                (NP
                  (NP
                    (NP (JJ methylational) (NN status))
                    (CC and)
                    (NP (NN mRNA) (NN expression)))
                  (PP (IN of)
                    (NP
                      (NP (NN DNA) (NNS methyltransferases))
                      (CC or)
                      (NP (JJ methyl-CpG-binding) (NNS proteins)))))))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Together))
      (, ,)
      (NP (DT these) (NNS data))
      (VP (VBP suggest)
        (NP (NN CpG) (JJ site-specific) (NN IRF-4) (NN promoter) (NN methylation))
        (PP (IN as)
          (NP
            (NP (DT a) (JJ putative) (NN mechanism))
            (PP (IN of)
              (NP
                (NP (VBN down-regulated) (NN IRF-4) (NN expression))
                (PP (IN in)
                  (NP (NN leukemia)))))))))
    (. .)))

(
  (S
    (NP (NN INTRODUCTION))))

(
  (S
    (S
      (NP
        (NP (JJ Chronic) (JJ myeloid) (NN leukemia))
        (PRN (-LRB- -LRB-)
          (NP (NN CML))
          (-RRB- -RRB-)))
      (VP (VBZ is)
        (NP
          (NP (DT a) (JJ clonal) (JJ myeloproliferative) (NN disorder))
          (PP (IN with)
            (NP
              (NP
                (NP (DT a) (JJ typical) (CD three) (JJ phased) (NN course))
                (PRN (-LRB- -LRB-)
                  (NP
                    (NP
                      (ADJP
                        (ADJP (JJ chronic))
                        (, ,)
                        (ADJP (VBN accelerated))))
                    (CC and)
                    (NP (JJ blastic) (NN phase)))
                  (-RRB- -RRB-)))
              (VP (VBG reflecting)
                (NP
                  (NP (DT the) (NN loss))
                  (PP (IN of)
                    (NP
                      (NP (NN differentiation))
                      (CC and)
                      (NP (JJ malignant) (NN progress))))))))
          (SBAR
            (WHNP (WDT which))
            (S
              (ADVP (RB inevitably))
              (VP (VBZ leads)
                (PP (TO to)
                  (NP
                    (NP (NN death))
                    (PP (IN after)
                      (NP
                        (NP (DT the) (JJ blastic) (NN phase))
                        (PRN (-LRB- -LRB-)
                          (NP (NN 1,2))
                          (-RRB- -RRB-))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN hallmark) (JJ genetic) (NN aberration))
        (PP (IN of)
          (NP (NN CML))))
      (VP (VBZ is)
        (NP
          (NP (DT a) (JJ reciprocal) (NN chromosomal) (NN translocation)
            (NP
              (NP (NN t))
              (PRN (-LRB- -LRB-)
                (NP (CD 9) (: ;) (CD 22))
                (-RRB- -RRB-))))
          (VP (VBG leading)
            (PP (TO to)
              (NP
                (NP (NN expression))
                (PP (IN of)
                  (NP
                    (NP (DT a) (NN bcr-abl) (NN fusion) (NN gene))
                    (, ,)
                    (NP
                      (NP (DT an) (JJ aberrant) (JJ activated) (NN tyrosine) (NN kinase))
                      (PRN (-LRB- -LRB-)
                        (NP (CD 2))
                        (-RRB- -RRB-)))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Treatment))
        (PP (IN with)
          (NP
            (NP (NN interferon) (NN α))
            (PRN (-LRB- -LRB-)
              (NP (NN IFN-α))
              (-RRB- -RRB-)))))
      (VP
        (VP (VBZ prolongs)
          (NP
            (NP (NN survival))
            (PP (IN of)
              (NP (NN CML) (NNS patients)))))
        (CC and)
        (VP (VBZ is)
          (VP (VBN associated)
            (PP (IN with)
              (NP
                (NP (DT a) (JJ complete) (JJ cytogenetic) (NN response))
                (PP (IN in)
                  (NP
                    (NP (CD 5–33) (NN %))
                    (PP (IN of)
                      (NP
                        (NP (NN CML) (NNS patients))
                        (PRN (-LRB- -LRB-)
                          (NP (NN 1,2))
                          (-RRB- -RRB-))))))))))))
    (. .)))

(
  (S
    (ADVP (RB Recently))
    (, ,)
    (NP (PRP we))
    (VP (VBD described)
      (NP
        (NP (DT an) (JJ impaired) (NN expression))
        (PP (IN of)
          (NP (DT the)
            (NP
              (NP (NN interferon) (JJ regulatory) (NN factor) (CD 4))
              (PRN (-LRB- -LRB-)
                (NP (NN IRF-4))
                (-RRB- -RRB-)))))
        (PP (IN in)
          (NP (NN CML))))
      (, ,)
      (S
        (VP (VBG correlating)
          (PP (IN with)
            (NP
              (NP (JJ poor) (NN response))
              (PP (TO to)
                (NP
                  (NP (JJ IFN-α) (NN treatment))
                  (PRN (-LRB- -LRB-)
                    (NP (CD 3))
                    (-RRB- -RRB-)))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN cause))
        (PP (IN of)
          (NP
            (NP (DT the) (NN silencing))
            (PP (IN of)
              (NP (NN IRF-4) (NN level))))))
      (VP (VBD remained)
        (ADJP (JJ unclear))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Interferon) (JJ regulatory) (NNS factors))
        (PRN (-LRB- -LRB-)
          (NP (NNS IRFs))
          (-RRB- -RRB-)))
      (VP (VBP are)
        (NP
          (NP (DT a) (NN family))
          (PP (IN of)
            (NP
              (NP (JJ transcriptional) (NNS regulators))
              (VP (VBN defined)
                (PP (IN by)
                  (NP
                    (NP (DT a) (JJ characteristic) (NN homology))
                    (PP (IN in)
                      (NP (PRP$ their) (JJ DNA-binding) (NN domain)))))))))))
    (. .)))

(
  (S
    (S
      (NP (PRP They))
      (VP (VBP play)
        (NP (DT an) (JJ important) (NN role))
        (PP (IN in)
          (NP
            (NP (DT the) (NN regulation))
            (PP (IN of)
              (NP
                (NP
                  (NP (JJ various) (NNS genes))
                  (PRN (-LRB- -LRB-)
                    (ADJP (JJ such)
                      (PP (IN as)
                        (NP
                          (NP (NNS IFNs))
                          (, ,)
                          (NP (NNS interleukins))
                          (, ,)
                          (NP (NN MHC) (NN class) (NN I/II)))))
                    (-RRB- -RRB-)))
                (, ,)
                (NP
                  (NP (NN apoptosis))
                  (CC and)
                  (NP
                    (NP (NN differentiation/maturation))
                    (PRN (-LRB- -LRB-)
                      (NP (NN 4–6))
                      (-RRB- -RRB-))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN IRF-4))
        (PRN (-LRB- -LRB-)
          (NP (NN ICSAT/Pip/MUM1/LSIRF))
          (-RRB- -RRB-)))
      (VP (VBZ is)
        (NP
          (NP (CD one) (NN member))
          (PP (IN with)
            (NP
              (ADJP (RB very) (JJ restricted))
              (NN expression) (NN pattern))))))
    (: :)
    (S
      (ADVP (RB Predominately))
      (NP
        (NP (NN B-))
        (CC and)
        (NP (VBN activated) (NNS T-lymphocytes)))
      (VP (VBP are)
        (ADJP
          (ADJP (NN IRF-4) (JJ positive))
          (PRN (-LRB- -LRB-)
            (NP (NN 7–11))
            (-RRB- -RRB-)))))
    (. .)))

(
  (S
    (PP (IN In) (NN contrast) (TO to)
      (NP (JJ other) (NNS IRFs)))
    (, ,)
    (NP
      (NP (NN expression))
      (PP (IN of)
        (NP (NN IRF-4))))
    (VP (MD cannot)
      (VP (VB be)
        (VP (VBN induced)
          (PP
            (PP (IN by)
              (NP (NNS IFNs)))
            (, ,)
            (CC but)
            (PP (IN by)
              (NP (NN antigen) (NN stimulation)))
            (, ,)
            (NP
              (NP (NN crosslinking))
              (PP (IN of)
                (NP
                  (NP
                    (NP
                      (NP (NN T-))
                      (CC or)
                      (NP (NN B-cell)))
                    (NNS receptors))
                  (CC or)
                  (NP
                    (NP (NN phorbol-myristate-acetate))
                    (PRN (-LRB- -LRB-)
                      (NP (NN 10,11))
                      (-RRB- -RRB-))))))))))
    (. .)))

(
  (S
    (S
      (S
        (ADJP (JJ Consistent)
          (PP (IN with)
            (NP
              (NP (DT the) (NN restriction))
              (PP (IN of)
                (NP (NN expression)))
              (PP (TO to)
                (NP (JJ immunocompetent) (NNS cells)))))))
      (, ,)
      (NP
        (NP (NNS mice))
        (PP (IN with)
          (NP
            (NP (NN deletion))
            (PP (IN of)
              (NP (NN IRF-4))))))
      (VP (VBD failed)
        (S
          (VP (TO to)
            (VP (VB develop)
              (NP
                (NP
                  (ADJP
                    (ADJP (JJ mature))
                    (CC and)
                    (ADJP (RB functionally) (JJ active)))
                  (NN B-))
                (CC and)
                (NP
                  (NP (NNS T-lymphocytes))
                  (PRN (-LRB- -LRB-)
                    (NP (CD 12))
                    (-RRB- -RRB-)))))))))
    (, ,)
    (CC and)
    (S
      (NP
        (NP (DT the) (JJ impaired) (NN expression))
        (PP (IN of)
          (NP (NN IRF-4)))
        (PP (IN in)
          (NP (NN CML))))
      (VP (VBD was)
        (ADVP (RB predominately))
        (VP (VBN found)
          (PP (IN in)
            (NP
              (NP (NNS T-cells))
              (PRN (-LRB- -LRB-)
                (NP (CD 3))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (S
      (NP (DT These) (NNS data))
      (VP (VBP suggest)
        (NP
          (NP (DT a) (JJ crucial) (NN role))
          (PP (IN for)
            (NP (NN IRF-4)))
          (PP (IN in)
            (NP
              (NP (DT the) (NN function))
              (PP (IN of)
                (NP (JJ immune) (NNS cells))))))))
    (. .)))

(
  (S
    (NP
      (NP (NN Methylation))
      (PP (IN of)
        (NP
          (NP (NN dinucleotide) (NN cytosine-guanosine) (NNS motifs))
          (PRN (-LRB- -LRB-)
            (NP (NN CpG))
            (-RRB- -RRB-))))
      (, ,)
      (ADVP (RB especially))
      (PP (IN in)
        (NP
          (NP (NN CpG) (NNS islands))
          (ADJP (JJ located)
            (PP (IN in)
              (NP (NN promoter) (NNS regions))))))
      (, ,))
    (VP (VBZ is)
      (NP
        (NP (CD one))
        (PP (IN of)
          (NP
            (NP (DT the) (NNS mechanisms))
            (PP (IN of)
              (NP (NN gene) (NN regulation)))
            (PP (IN in)
              (NP
                (NP (NNS mammals))
                (CC and)
                (NP
                  (NP (DT a) (JJ common) (NN event))
                  (PP (IN of)
                    (NP (NN gene) (NN silencing)))
                  (PP (IN in)
                    (NP
                      (NP (JJ human) (NNS neoplasias))
                      (PRN (-LRB- -LRB-)
                        (NP (NN 13,14))
                        (-RRB- -RRB-)))))))))))
    (. .)))

(
  (S
    (S
      (SBAR (IN As)
        (S
          (VP (VBN opposed)
            (PP (TO to)
              (NP (JJ normal) (NNS cells))))))
      (, ,)
      (NP
        (NP (NN hypermethylation))
        (PP (IN of)
          (NP (NN CpG) (NNS islands))))
      (VP (VBZ is)
        (NP
          (NP (DT a)
            (ADJP (RB frequently) (VBN observed))
            (NN phenomenon))
          (PP (IN in)
            (NP (DT every) (NN cancer) (NN type))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP
          (ADJP (FW De) (FW novo))
          (NN DNA) (NN methylation))
        (PP (IN of)
          (NP
            (NP (NNS genes))
            (PP (JJ such) (IN as)
              (NP
                (NP (NN cell) (NN cycle))
                (, ,)
                (NP (NN DNA) (NN repair))
                (, ,)
                (NP (NN apoptosis))
                (CC and)
                (NP (NN tumor) (NN suppressor) (NNS genes)))))))
      (VP (VBZ is)
        (ADVP (RB therefore))
        (VP (VBN thought)
          (S
            (VP (TO to)
              (VP (VB be)
                (VP (VBN involved)
                  (PP (IN in)
                    (NP
                      (NP (NN tumorigenesis))
                      (PRN (-LRB- -LRB-)
                        (NP (NN 15–17))
                        (-RRB- -RRB-)))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NNS Examples))
        (PP (IN for)
          (NP (JJ such) (JJ aberrated) (NNS genes))))
      (VP (VBP are)
        (NP
          (NP (NN MGMT))
          (, ,)
          (NP (NN DAPK))
          (, ,)
          (NP (NN p14ARF))
          (, ,)
          (NP (NN p15INK4b))
          (, ,)
          (NP (NN p16INK4a))
          (, ,)
          (NP (NN BRCA1))
          (, ,)
          (NP (NN CDH13))
          (CC and)
          (NP
            (NP (NN APAF-1))
            (PRN (-LRB- -LRB-)
              (NP (NN 17–19))
              (-RRB- -RRB-))))))
    (. .)))

(
  (S
    (PP (IN In)
      (NP (NN CML)))
    (, ,)
    (S
      (S
        (NP (NN methylation))
        (VP (VBZ is)
          (VP (VBN known)
            (S
              (VP (TO to)
                (VP (VB regulate)
                  (NP
                    (NP (NN expression))
                    (PP (IN of)
                      (NP
                        (NP (DT the)
                          (NP (NN c-abl))
                          (, ,)
                          (NP (DT the) (NN bcr) (NN gene))
                          (CC and)
                          (NP (NNS others)))
                        (PRN (-LRB- -LRB-)
                          (NP (NN 20–23))
                          (-RRB- -RRB-)))))))))))
      (, ,)
      (CC and)
      (S
        (NP
          (NP (DT the) (NN extent))
          (PP (IN of)
            (NP (NN methylation)))
          (PP (IN in)
            (NP (DT the) (NN c-abl) (NN promoter))))
        (VP (VBZ has)
          (VP (VBN been)
            (VP (VBN shown)
              (S
                (VP (TO to)
                  (VP (VB be)
                    (VP (VBN associated)
                      (PP (IN with)
                        (NP
                          (NP (JJ advanced) (NN disease))
                          (PRN (-LRB- -LRB-)
                            (NP (CD 24))
                            (-RRB- -RRB-)))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Hypermethylation))
        (PP (IN due) (TO to)
          (NP
            (NP (NN overexpression))
            (PP (IN of)
              (NP
                (NP (NN DNA) (NNS methyltransferases))
                (PRN (-LRB- -LRB-)
                  (NP (NNS DNMTs))
                  (-RRB- -RRB-)))))))
      (VP (VBZ remains)
        (NP
          (NP (CD one) (JJ possible) (NN explanation))
          (PP (IN for)
            (NP
              (NP
                (ADJP (FW de) (FW novo))
                (NN methylation))
              (PP (IN in)
                (NP (NN tumorigenesis))))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Recently))
      (, ,)
      (NP (NNS DNMTs))
      (VP (VBP have)
        (VP (VBN been)
          (VP (VBN shown)
            (S
              (VP (TO to)
                (VP (VB be)
                  (VP (VBN up-regulated)
                    (PP (IN in)
                      (NP (JJ hematopoietic) (NNS malignancies)))))))
            (PRN (-LRB- -LRB-)
              (NP (CD 25))
              (-RRB- -RRB-))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Methyl-CpG-binding) (NNS proteins))
        (PRN (-LRB- -LRB-)
          (NP (NN MBPs))
          (-RRB- -RRB-)))
      (VP
        (VP (VBP are)
          (VP (VBN thought)
            (S
              (VP (TO to)
                (VP (VB inhibit)
                  (NP
                    (NP (DT the) (NN binding))
                    (PP (IN of)
                      (NP (JJ transcriptional) (NNS factors)))
                    (PP (TO to)
                      (NP (DT the) (NN promoter)))))))))
        (CC and)
        (VP (VBP are)
          (ADVP (RB therefore))
          (VP (VBN discussed)
            (PP (IN as)
              (NP
                (NP (CD one) (NN mechanism))
                (PP (IN of)
                  (NP
                    (NP (NN transcription) (NN inhibition))
                    (PP (IN by)
                      (NP (NN hypermethylation) (-LRB- -LRB-) (CD 26) (-RRB- -RRB-)))))))))))
    (. .)))

(
  (S
    (PP (IN In)
      (NP (DT this) (NN work)))
    (, ,)
    (NP (PRP we))
    (VP (VBD studied)
      (NP
        (NP (NNS mechanisms))
        (PP (IN of)
          (NP (NN IRF-4) (NN gene) (NN expression) (NN silencing)))
        (PP (IN in)
          (NP (JJ leukemic) (NNS cells)))))
    (. .)))

(
  (S
    (S
      (NP (PRP We))
      (VP (VBD analyzed)
        (NP
          (NP (DT the) (NN IRF-4) (NN promoter) (NN region))
          (PP (IN for)
            (NP
              (NP (JJ genetic) (NNS aberrations))
              (CC and)
              (NP (JJ methylational) (NN status))))
          (PP (IN in)
            (NP
              (ADJP
                (ADJP (JJ IRF-4-positive))
                (CC and)
                (ADJP (JJ -negative)))
              (JJ hematopoietic) (NNS cells))))))
    (. .)))

(
  (S
    (NP
      (NP (NNS MATERIALS))
      (CC AND)
      (NP (NNS METHODS)))))

(
  (S
    (S
      (NP
        (NP (NN K-562))
        (, ,)
        (NP (NN Jurkat))
        (CC and)
        (NP (NN U-937)))
      (VP (VBD were)
        (VP (VBN obtained)
          (PP (IN from)
            (NP
              (NP
                (NP (DT the) (NN ATCC))
                (PRN (-LRB- -LRB-)
                  (NP
                    (NP (NNP American) (NN Type) (NN Culture) (NN Collection))
                    (, ,)
                    (NP (NNP Rockville) (, ,) (NNP USA)))
                  (-RRB- -RRB-)))
              (CC and)
              (NP
                (NP (NN EM-2))
                (, ,)
                (NP
                  (NP (CD LAMA-84))
                  (, ,)
                  (NP (NN CML-T1))
                  (, ,)
                  (NP (CD BV-173))
                  (, ,)
                  (NP (CD SD-1))
                  (CC and)
                  (NP (CD RPMI-8226))))))
          (PP (IN from)
            (NP
              (NP (DT the) (JJ DSMZ))
              (PRN (-LRB- -LRB-)
                (NP (NNP Deutsche) (NNP Sammlung) (NN von) (NNP Mikroorganismen) (NNP und) (NNP Zellkulturen) (NNP GmbH) (, ,) (NNP Braunschweig) (, ,) (NNP Germany))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT All) (NN cell) (NNS lines))
        (, ,)
        (PP (IN except)
          (NP
            (NP (CD BV-173))
            (, ,)
            (NP (CD SD-1))
            (CC and)
            (NP (CD RPMI-8226))))
        (, ,))
      (VP (VBD were)
        (ADJP (JJ IRF-4-negative))))
    (. .)))

(
  (S
    (S
      (NP (DT All) (NN cell) (NNS lines))
      (VP (VBD were)
        (VP (VBN maintained)
          (PP (IN at)
            (NP
              (ADJP (CD 5) (NN %))
              (NN CO2)))
          (PP (IN in)
            (NP
              (NP (NN RPMI) (CD 1640) (NN medium))
              (PP (IN with)
                (NP
                  (NP
                    (NP
                      (ADJP (CD 1) (NN %))
                      (NN glutamine))
                    (PRN (-LRB- -LRB-)
                      (NP (NNP Gibco/BRL) (NNP Eggenstein) (, ,) (NNP Germany))
                      (-RRB- -RRB-)))
                  (VP (VBN supplemented)
                    (PP (IN with)
                      (NP
                        (NP
                          (NP
                            (ADJP (CD 10) (NN %))
                            (JJ fetal) (NN calf) (NN serum))
                          (PRN (-LRB- -LRB-)
                            (NP (NN Gibco/BRL))
                            (-RRB- -RRB-)))
                        (, ,)
                        (NP
                          (NP
                            (ADJP (CD 1) (NN %))
                            (NN penicillin/streptomycin))
                          (PRN (-LRB- -LRB-)
                            (NP (NNP Biochrom) (, ,) (NNP Berlin) (, ,) (NNP Germany))
                            (-RRB- -RRB-)))))))))))))
    (. .)))

(
  (S
    (S
      (SBAR
        (WHADVP (WRB When))
        (S
          (VP (VBN indicated))))
      (, ,)
      (NP (NNS cells))
      (VP (VBD were)
        (VP (VBN treated)
          (PP (IN with)
            (NP
              (NP
                (NP (NN 5-aza-2-deoxycytidine))
                (PRN (-LRB- -LRB-)
                  (NP (NN AzadC))
                  (-RRB- -RRB-)))
              (CC or)
              (NP
                (NP (NN 5-azacytidine))
                (PRN (-LRB- -LRB-)
                  (NP (NN AzaC))
                  (-RRB- -RRB-)))))
          (PRN (-LRB- -LRB-)
            (NP (NN Sigma))
            (, ,)
            (NP
              (NP (NNP Taufkirchen))
              (, ,)
              (NP (NNP Germany)))
            (-RRB- -RRB-))
          (PP (IN for)
            (NP (JJ different) (NN time) (NNS periods))))))
    (. .)))

(
  (S
    (S
      (S
        (VP (VBG Owing)
          (PP (TO to)
            (NP (PRP$ their) (JJ chemical) (NN instability)))))
      (NP (JJ fresh) (NNS substances))
      (VP (VBD were)
        (VP (VBN re-added)
          (NP (DT every) (CD 24) (NN h)))))
    (. .)))

(
  (S
    (PP (IN For)
      (NP
        (NP (NN analysis))
        (PP (IN of)
          (NP
            (NP (DT the) (NN IRF-4) (NN promoter) (NN region))
            (PP (IN for)
              (NP
                (NP (JJ permanent) (NNS aberrations))
                (PP (JJ such) (IN as)
                  (NP
                    (NP (NNS insertions/deletions))
                    (CC or)
                    (NP (NN mutation))))))))))
    (, ,)
    (NP (PRP we))
    (VP (VBN PCR-amplified)
      (NP
        (NP (CD two) (NNS fragments))
        (PP (IN from)
          (NP (JJ genomic) (NN DNA)))
        (, ,)
        (SBAR
          (WHNP (WDT which))
          (S
            (VP (VBD was)
              (VP (VBN extracted)
                (PP (IN from)
                  (NP
                    (NP (VBN depicted) (NN cell) (NNS lines))
                    (PP (IN with)
                      (NP
                        (NP
                          (NP (DT a) (JJ commercial) (NN kit))
                          (PRN (-LRB- -LRB-)
                            (NP
                              (NP (NN Qiagen))
                              (, ,)
                              (NP (NNP Hilde) (, ,) (NNP Germany)))
                            (-RRB- -RRB-)))
                        (SBAR (IN as)
                          (S
                            (VP (VBN recommended))))))))))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NNS primers))
      (VP (VBD were)
        (NP
          (NP (CD 1-forward))
          (: :)
          (NP
            (NP (CD 5′-TTGAGATGGAGTCTTGCTCTGT-3′))
            (, ,)
            (NP (NN 1-reverse)))
          (: :)
          (NP (CD 5′-CCAGGACCTCAGGAGGCCAGTCA-3′))
          (: ;)
          (NP (CD 2-forward))
          (: :)
          (NP
            (NP (CD 5′-AGCGGTGAAACTGAGAGTGCGAGGT-3′))
            (, ,)
            (NP (NN 2-reverse)))
          (: :)
          (NP (CD 5′-GCCACATCGCTGCAGTTTAG-3′)))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NNS products))
      (VP (VBD were)
        (VP (VBN cloned)
          (PP (IN with)
            (NP (DT the) (NN ‘TOPO) (NN TA) (NN cloning) (CD kit’)))
          (PRN (-LRB- -LRB-)
            (NP
              (NP (NNP Invitrogen))
              (, ,)
              (NP (NNP Groningen) (, ,) (NNP The) (NNP Netherlands)))
            (-RRB- -RRB-)))))
    (. .)))

(
  (S
    (S
      (PP (IN After)
        (NP
          (NP (JJ bacterial) (NN amplification))
          (PP (IN of)
            (NP (DT the) (VBN cloned) (NN PCR) (NNS fragments)))
          (PP (IN by)
            (NP (JJ standard) (NNS procedures)))))
      (, ,)
      (NP
        (NP
          (QP (IN at) (JJS least) (CD three))
          (NNS clones))
        (PP (IN from)
          (NP (DT each) (NN sample))))
      (VP (VBD were)
        (VP (VBN sequenced)
          (PP (IN with)
            (NP
              (NP (DT an) (JJ automated) (NN sequencer))
              (PRN (-LRB- -LRB-)
                (NP
                  (NP (NN ABI) (NN Prism) (NN 377))
                  (, ,)
                  (NP (VBN Applied) (NN Bio-systems))
                  (, ,)
                  (NP (NNP Foster) (NNP City) (, ,) (NNP USA)))
                (-RRB- -RRB-))))
          (SBAR (IN as)
            (S
              (VP (VBN recommended)
                (PP (IN by)
                  (NP (DT the) (NN manufacturer)))))))))
    (. .)))

(
  (S
    (S
      (S
        (VP (TO To)
          (VP (VB analyze)
            (NP (DT the) (NN IRF-4) (JJ transcriptional) (NN level)))))
      (, ,)
      (NP (NN RNA))
      (VP (VBD was)
        (VP (VBN extracted)
          (PP (IN from)
            (NP
              (NP (NNS cells))
              (VP (VBG using)
                (NP
                  (NP (DT the) (JJ commercial) (NN RNAzol-kit))
                  (PRN (-LRB- -LRB-)
                    (NP
                      (NP (NNP Paesel))
                      (, ,)
                      (NP (NN Frankfurt))
                      (, ,)
                      (NP (NNP Germany)))
                    (-RRB- -RRB-)))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT An) (NN aliquot))
        (PP (IN of)
          (NP (CD 1) (NN μg) (JJ total) (NN RNA))))
      (VP (VBD was)
        (VP (VBN used)
          (PP (IN for)
            (NP (NN cDNA) (NN synthesis)))
          (SBAR (IN as)
            (S
              (VP (VBN described)
                (ADVP (RB previously))
                (PRN (-LRB- -LRB-)
                  (NP (CD 27))
                  (-RRB- -RRB-))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN RNA) (NN expression) (NN analysis))
        (PP (IN for)
          (NP
            (NP (NN IRF-4))
            (CC and)
            (NP (DT the) (NN reference) (NN gene) (NN β-actin)))))
      (VP (VBD was)
        (VP (VBN carried)
          (PRT (RP out))
          (PP (IN by)
            (NP (JJ semi-quantitative) (NN PCR))))
        (SBAR (IN as)
          (S
            (VP (VBN described)
              (ADVP (RB previously))
              (PRN (-LRB- -LRB-)
                (NP (NN 3,27))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (S
      (NP (NN PCR) (NNS products))
      (VP (VBD were)
        (VP (VBN verified)
          (PP (IN by)
            (NP (JJ automated) (NN sequencing))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP
          (NP (NN PCR) (NNS primers))
          (CC and)
          (NP (NNS conditions)))
        (PP (IN for)
          (NP
            (NP (NN expression) (NN analysis))
            (PP (IN of)
              (NP
                (NP
                  (NP (NN DNMT))
                  (CC or)
                  (NP (NN MBP)))
                (PRN (-LRB- -LRB-)
                  (NP
                    (NP (NN DNMT1) (NN DNMT3A))
                    (, ,)
                    (NP (NN DNMT3B))
                    (, ,)
                    (NP (NN MeCP)))
                  (, ,)
                  (NP
                    (NP (NN MBD1))
                    (, ,)
                    (NP (NN MBD2))
                    (CC and)
                    (NP (NN MBD4)))
                  (-RRB- -RRB-)))))))
      (VP (VBD were)
        (VP (VBN published)
          (NP
            (NP (NN elsewhere))
            (PRN (-LRB- -LRB-)
              (NP (CD 28))
              (-RRB- -RRB-))))))
    (. .)))

(
  (S
    (S
      (PP (IN For)
        (NP
          (NP (NN analysis))
          (PP (IN of)
            (NP (NN IRF-4) (NN protein) (NN expression)))))
      (, ,)
      (NP (DT a) (JJ standard) (NN immunoblotting) (NN assay))
      (VP (VBD was)
        (VP (VBN performed)
          (SBAR (IN as)
            (S
              (VP (VBN described)
                (ADVP (RB previously))
                (PRN (-LRB- -LRB-)
                  (NP (CD 29))
                  (-RRB- -RRB-))))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Briefly))
      (, ,)
      (NP (NN protein) (NNS lysates))
      (VP (VBD were)
        (VP (VBN generated)
          (PP (IN by)
            (S
              (VP (VBG incubating)
                (NP (CD 1) (NN ×) (CD 106) (NNS cells))
                (PP (IN in)
                  (NP
                    (NP
                      (ADJP (CD 100) (NN µl))
                      (NN RIPA) (NN buffer))
                    (PRN (-LRB- -LRB-)
                      (NP
                        (NP
                          (ADJP (CD 1) (NN %))
                          (NN NP-40))
                        (, ,)
                        (NP
                          (ADJP (CD 0.5) (NN %))
                          (NN sodiumdesoxycholate))
                        (, ,)
                        (NP
                          (ADJP (CD 0.1) (NN %))
                          (NN SDS))
                        (, ,)
                        (NP
                          (ADJP (CD 100) (NN µg/ml))
                          (NN phenylmethylsulfonyl) (NN fluoride))
                        (, ,)
                        (NP
                          (ADJP (CD 10) (NN µl/ml))
                          (NN protease-inhibitory-mix))
                        (, ,)
                        (NP
                          (NP (CD 1) (NN µmol/ml) (NN sodiumorthovanadate))
                          (PP (IN in)
                            (NP (JJ phosphate-buffered) (NN saline)))))
                      (-RRB- -RRB-))))
                (PP (IN for)
                  (NP
                    (NP (CD 30) (NN min))
                    (PP (IN on)
                      (NP (NN ice)))))))))))
    (. .)))

(
  (S
    (S
      (PP (IN After)
        (NP (NN centrifugation)))
      (, ,)
      (NP
        (NP (NN protein) (NN concentration))
        (PP (IN of)
          (NP (DT the) (NN supernatant))))
      (VP (VBD was)
        (VP (VBN determined)
          (PP (IN by)
            (NP (NN BCA-method)))
          (PRN (-LRB- -LRB-)
            (NP (NN Pierce))
            (, ,)
            (NP
              (NP (NNP Rockford))
              (, ,)
              (NP (NN IL)))
            (-RRB- -RRB-)))
        (SBAR (IN as)
          (S
            (VP (VBN recommended))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Protein) (NNS lysates))
        (PRN (-LRB- -LRB-)
          (NP (CD 70–100) (NN µg))
          (-RRB- -RRB-)))
      (VP (VBD were)
        (VP
          (VP (VBN electrophoresed)
            (PP (IN on)
              (NP (NN polyacrylamide) (NNS gels))))
          (CC and)
          (VP (VBN transferred)
            (PP (TO to)
              (NP
                (NP (DT a) (NN PVDF-membrane))
                (PRN (-LRB- -LRB-)
                  (NP
                    (NP (NN Immobilon) (NN P))
                    (, ,)
                    (NP (NN 0.45) (NN µm))
                    (: ;)
                    (NP (NNP Millipore) (, ,) (NNP Eschborn) (, ,) (NNP Germany)))
                  (-RRB- -RRB-))))))))
    (. .)))

(
  (S
    (S
      (NP (NNS Membranes))
      (VP (VBD were)
        (VP
          (VP (VBN blocked)
            (PP (IN with)
              (NP
                (NP
                  (NP
                    (ADJP (CD 2.5) (NN %))
                    (NN blocking) (NN reagent))
                  (PRN (-LRB- -LRB-)
                    (NP (NNP Boehringer) (NNP Mannheim) (, ,) (NNP Germany))
                    (-RRB- -RRB-)))
                (PP (IN in)
                  (NP
                    (NP (NN TBST) (NN buffer))
                    (PRN (-LRB- -LRB-)
                      (FRAG
                        (NP (CD 4.44) (NN g/l) (NN Tris–HCL))
                        (, ,)
                        (NP (CD 2.65) (NN g/l) (NN TrisOH))
                        (, ,)
                        (NP
                          (NP
                            (NP
                              (ADJP (CD 8.07) (NN g/l))
                              (NN NaCl))
                            (, ,)
                            (NP
                              (ADJP (CD 0.2) (NN g/l))
                              (NN KCl))
                            (CC and)
                            (NP
                              (ADJP (CD 500) (NN µl/l))
                              (NN Tween-20)))
                          (PP (IN in)
                            (NP (NNP H2O)))))
                      (-RRB- -RRB-)))))))
          (CC and)
          (VP
            (ADVP (RB subsequently))
            (VBN incubated)
            (PP (IN with)
              (NP (JJ primary) (NN antibody)))))
        (SBAR (IN as)
          (S
            (VP (VBN indicated)
              (NP (CC and)
                (NP
                  (NP
                    (NP (NN horseradish) (JJ peroxidase-conjugated) (JJ secondary) (NN antibody))
                    (, ,)
                    (NP (JJ anti-mouse)
                      (CC or)
                      (NN anti-goat) (NN IgG)))
                  (PRN (-LRB- -LRB-)
                    (NP
                      (NP (NN DAKO))
                      (, ,)
                      (NP (NNP Hamburg) (, ,) (NNP Germany)))
                    (-RRB- -RRB-)))
                (, ,)
                (ADVP (RB respectively))))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NNS membranes))
      (VP (VBD were)
        (ADVP (RB then))
        (VP (VBN developed)
          (PP (IN with)
            (NP
              (NP (DT an) (NN ECL) (NN detection) (NN kit))
              (PRN (-LRB- -LRB-)
                (NP (NNP Amersham) (NNP Pharmacia) (NNP Biotech) (, ,) (NNP Freiburg) (, ,) (NNP Germany))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (JJ primary) (NNS antibodies))
      (VP (VBD were)
        (NP
          (NP
            (NP
              (NP (NN goat) (NN anti-IRF-4/ICSAT))
              (PRN (-LRB- -LRB-)
                (NP (NN M-17))
                (-RRB- -RRB-)))
            (PRN (-LRB- -LRB-)
              (NP
                (NP
                  (NP (NNP Santa) (NNP Cruz))
                  (NN Biotechnology) (, ,) (NNP Santa) (NNP Cruz))
                (, ,)
                (NP (NN CA)))
              (-RRB- -RRB-)))
          (CC and)
          (NP
            (NP
              (NP (NN mouse) (NN anti-β-actin))
              (PRN (-LRB- -LRB-)
                (NP (NN AC-74))
                (-RRB- -RRB-)))
            (PRN (-LRB- -LRB-)
              (NP (NN Sigma))
              (-RRB- -RRB-))))))
    (. .)))

(
  (S
    (S
      (NP (NN DNA))
      (VP (VBD was)
        (VP (VBN extracted)
          (PP (IN with)
            (NP
              (NP
                (NP (DT a) (JJ commercial) (NN kit))
                (PRN (-LRB- -LRB-)
                  (NP (NN Qiagen))
                  (-RRB- -RRB-)))
              (SBAR (IN as)
                (S
                  (VP (VBN recommended)))))))))
    (. .)))

(
  (S
    (SBAR (IN Since)
      (S
        (NP
          (NP (DT the) (NN restriction) (NN ability))
          (PP (IN of)
            (NP (JJ several) (NNS endonucleases))))
        (VP (VBZ is)
          (VP (VBN inhibited)
            (PP (IN by)
              (NP
                (NP (NN methylation))
                (PP (IN of)
                  (NP (PRP$ their) (NN target) (NN sequence)))))))))
    (, ,)
    (NP (PRP we))
    (VP (VBD used)
      (NP
        (NP (JJ methylation-sensitive) (NNS enzymes) (NN HpaII))
        (CC and)
        (NP
          (NP
            (NP
              (NP (NNP HaeII-isochizomer) (NNP Bsp143II))
              (CC and)
              (NP (NNP Bsh1236I)))
            (PRN (-LRB- -LRB-)
              (NP
                (NP (NNP MBI) (NNP Fermentas))
                (, ,)
                (NP (JJ St) (NN Leon-Rot))
                (, ,)
                (NP (NNP Germany)))
              (-RRB- -RRB-)))
          (PRN (-LRB- -LRB-)
            (NP (CD 20,24))
            (-RRB- -RRB-)))))
    (. .)))

(
  (S
    (S
      (PP (IN As)
        (NP (NN control)))
      (NP
        (NP (DT the) (JJ methylation-resistant) (NN enzyme) (NN MspI))
        (CC and)
        (NP
          (NP
            (NP (DT an) (NN enzyme))
            (PP (IN with)
              (NP
                (NP (DT no) (NN recognition) (NN site))
                (PP (IN in)
                  (NP (DT the) (NN target) (NN promoter))))))
          (, ,)
          (NP (NN EcoRI))
          (, ,)))
      (VP (VBD were)
        (VP (VBN used))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN DNA))
        (PRN (-LRB- -LRB-)
          (NP (CD 0.8) (NN µg))
          (-RRB- -RRB-)))
      (VP (VBD was)
        (VP
          (VP (VBN digested)
            (PP (IN by)
              (NP
                (NP (CD 40) (NN U))
                (NP
                  (NP (DT the) (JJ respective) (NN enzyme))
                  (PP (IN for)
                    (NP (CD 6) (NN h)))))))
          (CC and)
          (VP (, ,)
            (PP (TO to)
              (S
                (VP (VB ensure)
                  (NP (JJ complete) (NN cleavage)))))
            (, ,)
            (NP
              (NP (JJ additional) (CD 20) (NN U))
              (PP (IN for)
                (NP (CD 16) (NN h))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP
          (QP (RB Thereafter) (CD 100))
          (NN ng))
        (PP (IN of)
          (NP (JJ digested) (NN DNA))))
      (VP (VBD was)
        (VP (VBN used)
          (PP (TO to)
            (NP
              (NP (DT a) (NN PCR) (NN amplification))
              (PP (IN of)
                (NP
                  (NP
                    (NP (CD two) (NNS fragments))
                    (PRN (-LRB- -LRB-)
                      (NP
                        (NP (NNP F1))
                        (CC and)
                        (NP (NNP F2)))
                      (-RRB- -RRB-)))
                  (VP (VBG spanning)
                    (NP
                      (NP (NN part))
                      (PP (IN of)
                        (NP (DT the)
                          (NP
                            (NP
                              (NP (NN IRF-4) (NN promoter))
                              (PRN (-LRB- -LRB-)
                                (NP (CD 30))
                                (-RRB- -RRB-)))
                            (PRN (-LRB- -LRB-)
                              (NP (NNP GenBank) (NNP U52683))
                              (: ;)
                              (S
                                (VP (VB see)
                                  (NP (NN Figure) (NN 3A))))
                              (-RRB- -RRB-))))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NNS sequences))
        (PP (IN of)
          (NP (DT the) (NNS primers))))
      (VP (VBD were)
        (NP
          (NP (CD F1-forward))
          (: :)
          (NP
            (NP (CD 5′-TTGAGATGGAGTCTTGCTCTGT-3′))
            (, ,)
            (NP (NN F1-reverse)))
          (: :)
          (NP
            (NP (CD ATCACTTCCAGACTTCAGTTCACCT-3′))
            (PRN (-LRB- -LRB-)
              (NP (CD 341) (NN bp))
              (-RRB- -RRB-)))
          (: ;)
          (NP (NN F2-forward))
          (: :)
          (NP
            (NP (CD 5′-AAGGTGAACTGAAGTCTGGAAGTGA-3′))
            (, ,)
            (NP (NN F2-reverse)))
          (: :)
          (NP
            (NP (CD 5′-CCAGGACCTCAGGAGGCCAGTCA-3′))
            (PRN (-LRB- -LRB-)
              (NP (CD 474) (NN bp))
              (-RRB- -RRB-))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NN PCR) (NNS conditions))
      (VP (VBD were)
        (VP (VBN described)
          (ADVP (RB elsewhere))
          (PRN (-LRB- -LRB-)
            (NP (CD 3))
            (-RRB- -RRB-)))))
    (. .)))

(
  (S
    (S
      (NP (NN PCR))
      (VP (VBD was)
        (VP (VBN performed)
          (PP (IN with)
            (NP
              (NP (DT an) (NN annealing) (NN temperature))
              (PP (IN of)
                (NP
                  (QP (CD 62°C)
                    (CC and)
                    (CD 35))
                  (NNS cycles))))))))
    (. .)))

(
  (S
    (S
      (SBAR
        (WHADVP (WRB When))
        (S
          (NP (NN DNA))
          (VP (VBD was)
            (VP (VBN methylated)
              (PP (IN at)
                (NP (JJ specific) (NNS sites)))))))
      (, ,)
      (NP (DT the) (JJ sensitive) (NNS enzymes))
      (VP (VBD were) (RB not)
        (ADJP (JJ able)
          (S
            (VP (TO to)
              (VP (VB digest)
                (NP
                  (NP (DT the)
                    (NP (NN DNA))
                    (CC and)
                    (NP (NN amplification)))
                  (VP (VBD took)
                    (NP (NN place))))))))))
    (: ;)
    (S
      (PP (IN in)
        (NP
          (NP (NN case))
          (PP (IN of)
            (NP (NN no) (NN methylation)))))
      (, ,)
      (S
        (S
          (NP (NN DNA))
          (VP (VBD was)
            (VP (VBN digested))))
        (CC and)
        (S
          (NP (DT no) (NN product))
          (VP (VBD was)
            (VP (VBN generated))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NN PCR) (NNS products))
      (VP
        (VP (VBD were)
          (VP (VBN electrophoresed)
            (PP (IN on)
              (NP (DT a)
                (ADJP (CD 3) (NN %))
                (NN agarose) (NN gel)))))
        (, ,)
        (VP (VBD were)
          (VP
            (VP (VBN stained)
              (PP (IN with)
                (NP (NN ethidium) (NN bromide))))
            (CC and)
            (VP (VBN photographed))))))
    (. .)))

(
  (S
    (S
      (NP (NN PCR) (NNS products))
      (VP (VBD were)
        (VP (VBN verified)
          (PP (IN by)
            (NP (JJ automated) (NN sequencing))))))
    (. .)))

(
  (S
    (S
      (NP (NN DNA))
      (VP (VBD was)
        (VP (VBN extracted)
          (SBAR (IN as)
            (S
              (VP (VBN described)
                (ADVP (RB above))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Bisulfite) (NN treatment))
        (PP (IN of)
          (NP (NN DNA)))
        (, ,)
        (VP (VBG leading)
          (PP (TO to)
            (NP
              (NP
                (NP (NN conversion))
                (PP (IN of)
                  (NP (JJ unmethylated) (NN cytosine)))
                (PP (TO to)
                  (NP (NN uracil) (NNS residues))))
              (CC and)
              (NP
                (NP (DT no) (NN change))
                (PP (IN of)
                  (NP (VBN methylated) (NN cytosine) (NNS residues)))))))
        (, ,))
      (VP (VBD was)
        (VP (VBN performed)
          (SBAR (IN as)
            (S
              (VP (VBN described)
                (PP (IN as)
                  (NP (VBZ follows)))))))))
    (. .)))

(
  (S
    (ADVP (RB Briefly))
    (, ,)
    (NP
      (NP
        (NP (CD 1) (NN µg))
        (PP (IN of)
          (NP (NN DNA))))
      (CC and)
      (NP
        (NP (CD 2) (NN µg))
        (PP (IN of)
          (NP
            (NP
              (NP
                (NP
                  (NP (NN poly))
                  (PRN (-LRB- -LRB-)
                    (NP (NN dA–dT))
                    (-RRB- -RRB-)))
                (PRN (-LRB- -LRB-)
                  (NP (NN poly) (-LRB- -LRB-) (CD dA–dT))
                  (-RRB- -RRB-)))
              (NNS copolymers))
            (PRN (-LRB- -LRB-)
              (NP (NNP Amersham) (NNP Pharmacia) (NNP Biotech))
              (-RRB- -RRB-))))))
    (VP (VBD were)
      (VP (VBN denaturated)
        (PP (IN for)
          (NP
            (NP (CD 20) (NN min))
            (PP (IN at)
              (NP
                (NP (NN 42°C))
                (PP (IN in)
                  (NP
                    (NP
                      (ADJP (CD 0.3) (NN M))
                      (NN NaOH))
                    (PP (IN in)
                      (NP
                        (NP (DT a) (NN volume))
                        (PP (IN of)
                          (NP (CD 50) (NN µl)))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Fresh) (NNS solutions))
        (PP (IN of)
          (NP
            (NP (CD 30) (NN µl))
            (PP (IN of)
              (NP
                (NP
                  (NP
                    (ADJP (CD 10) (NN mM))
                    (NN hydrochinon))
                  (PRN (-LRB- -LRB-)
                    (NP (NN Sigma))
                    (-RRB- -RRB-)))
                (CC and)
                (NP
                  (NP
                    (NP (CD 530) (NN µl))
                    (PP (IN of)
                      (NP
                        (ADJP (CD 3) (NN M))
                        (NN sodium) (NN bisulfite))))
                  (PRN (-LRB- -LRB-)
                    (NP
                      (NP (NN pH) (CD 5.0))
                      (: ;)
                      (NP (NN Sigma)))
                    (-RRB- -RRB-))))))))
      (VP (VBD were)
        (VP (VBN added))))
    (, ,)
    (S
      (NP (DT the) (NN solution))
      (VP (VBD was)
        (ADVP (RB gently))
        (VP (VBN mixed))
        (, ,)
        (S
          (VP
            (VP (VBN overlayed)
              (PP (IN with)
                (NP (JJ mineral) (NN oil))))
            (CC and)
            (VP (VBN incubated)
              (PP (IN in)
                (NP (DT the) (NN dark)))
              (PP (IN for)
                (NP
                  (NP (CD 12–13) (NN h))
                  (PP (IN at)
                    (NP (NN 50°C))))))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (JJ aqueous) (NN phase))
      (VP (VBD was)
        (VP (VBN recovered)
          (S
            (VP (VBG using)
              (NP
                (NP (DT the) (JJ ‘Wizard) (NN DNA) (NN clean-up) (NN system’))
                (PRN (-LRB- -LRB-)
                  (NP
                    (NP (NNP Promega))
                    (, ,)
                    (NP (NNP Mannheim) (, ,) (NNP Germany)))
                  (-RRB- -RRB-))))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (VBN purified) (NN DNA))
      (VP (VBD was)
        (VP
          (VP
            (ADVP (RB subsequently))
            (VBN mixed)
            (PP (IN with)
              (NP
                (NP
                  (ADJP (CD 1) (NN M))
                  (NN NaOH))
                (PP (TO to)
                  (NP
                    (NP (DT a) (JJ final) (NN concentration))
                    (PP (IN of)
                      (NP (CD 0.3) (NN M))))))))
          (CC and)
          (VP (VBN incubated)
            (PP (IN for)
              (NP (CD 20) (NN min)))
            (PP (IN at)
              (NP
                (NP (NN 37°C))
                (S
                  (VP (TO to)
                    (VP (VB ensure)
                      (NP (JJ complete) (NN desulfonisation)))))))))))
    (. .)))

(
  (S
    (S
      (NP (NN DNA))
      (VP (VBD was)
        (ADJP (NN ethanol) (JJ precipitated))
        (PP (IN in)
          (NP
            (NP (DT the) (NN presence))
            (PP (IN of)
              (NP
                (NP (CD 1/10) (NN vol))
                (PP (IN of)
                  (NP
                    (ADJP (CD 3) (NN M))
                    (NN sodium) (NN acetate)))))))
        (, ,)
        (S
          (VP
            (VP (VBN washed)
              (PP (IN with)
                (NP
                  (ADJP (CD 70) (NN %))
                  (NN ethanol))))
            (CC and)
            (VP (VBN resuspended)
              (PP (IN in)
                (NP
                  (QP (CD 50))
                  (NN µl) (NN H2O))))))))
    (. .)))

(
  (S
    (NP
      (NP (JJ Subsequent) (NN PCR) (NN amplification))
      (PP (IN of)
        (NP (CD 4) (NN µl) (JJ bisulfite-treated) (NN DNA))))
    (VP (VBD was)
      (VP (VBN used)
        (PP (IN for)
          (NP
            (NP (NN cloning))
            (PP (IN of)
              (NP
                (NP (CD two) (NNS fragments))
                (PP (IN of)
                  (NP (DT the)
                    (NP
                      (NP (NN IRF-4) (NN promoter))
                      (PRN (-LRB- -LRB-)
                        (NP
                          (NP (NN BS-I))
                          (CC and)
                          (NP (NN BS-II)))
                        (-RRB- -RRB-)))))))))
        (PP (IN into)
          (NP
            (NP (NN pCR2.1) (NN vector))
            (PP (IN with)
              (NP
                (NP
                  (NP
                    (NP (DT the) (NN ‘TOPO) (NN TA) (NN cloning))
                    (NN kit’))
                  (PRN (-LRB- -LRB-)
                    (NP (NN Invitrogen))
                    (-RRB- -RRB-)))
                (PRN (-LRB- -LRB-)
                  (S
                    (VP (VB see)
                      (NP (NN Figure) (NN 3A))))
                  (-RRB- -RRB-))))))))
    (. .)))

(
  (S
    (NP
      (NP (DT The) (NNS primers))
      (VP (VBN used)
        (PP (IN for)
          (NP
            (NP (NN PCR) (NN amplification))
            (PP (IN of)
              (NP (DT the) (NN BS-I)
                (CC and)
                (NN BS-II) (NNS fragments)))))))
    (VP (VBP contain)
      (NP
        (NP
          (NP (DT the) (JJ putative) (JJ altered) (NN sequence))
          (PP (IN of)
            (NP
              (NP (DT the) (JJ sense) (NN strand))
              (PP (IN due) (TO to)
                (NP
                  (NP (NN bisulfite) (NN treatment))
                  (PRN (-LRB- -LRB-)
                    (S
                      (NP (VBN converted) (NN cytosine) (NNS residues))
                      (VP (VBP are)
                        (VP (VBN written)
                          (PP (IN in)
                            (NP (JJ bold) (NNS letters))))))
                    (-RRB- -RRB-)))))))
        (: :)
        (NP
          (NP (JJ BS-I-forward) (NN 5′-TATTTGGATTTTTAGGGAGTTTTTTTT-3′))
          (, ,)
          (NP
            (NP (JJ BS-I-reverse) (NN 5′-ACCCAACTCCCTTAAACTATTAAACT-3′))
            (PRN (-LRB- -LRB-)
              (NP (CD 187) (NN bp))
              (-RRB- -RRB-))))
        (: ;)
        (NP (NN BS-II-forward) (NN 5′-AGTTTAATAGTTTAAGGGAGTTGGGT-3′))
        (, ,)
        (NP
          (NP (JJ BS-II-reverse) (NN 5′-CTCACCCTAAACTCAAAACTAAAAAC-3′))
          (PRN (-LRB- -LRB-)
            (NP (CD 674) (NN bp))
            (-RRB- -RRB-)))))
    (. .)))

(
  (S
    (S
      (PP (IN After)
        (NP
          (NP (JJ bacterial) (NN amplification))
          (PP (IN of)
            (NP (DT the) (VBN cloned) (NN PCR) (NNS fragments)))
          (PP (IN by)
            (NP (JJ standard) (NNS procedures)))))
      (, ,)
      (NP
        (NP (CD eight) (NNS clones))
        (PP (IN from)
          (NP (DT each) (NN sample))))
      (VP (VBD were)
        (VP (VBN sequenced)
          (PP (IN with)
            (NP
              (NP (DT an) (JJ automated) (NN sequencer))
              (PRN (-LRB- -LRB-)
                (NP (NN ABI) (NN Prism) (NN 377) (, ,) (VBN Applied) (NN Biosystems))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NN IRF-4) (NN promoter-reporter) (NN gene) (NN construct))
      (VP (VBD was)
        (ADVP (RB generously))
        (VP (VBN provided)
          (PP (IN by)
            (NP
              (NP (NNP J.) (NNP Hiscott))
              (PRN (-LRB- -LRB-)
                (NP (CD 31))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (S
      (S
        (NP (NNS Constructs))
        (VP (VBD were)
          (VP (VBN methylated)
            (ADVP (FW in) (FW vitro))
            (PP (IN with)
              (NP
                (NP (NN CpG) (NN Methylase))
                (PRN (-LRB- -LRB-)
                  (NP (NN M.Sss) (NN I))
                  (-RRB- -RRB-))))
            (SBAR (IN as)
              (S
                (VP (VBN recommended)
                  (PP (IN by)
                    (NP
                      (NP (DT the) (NN manufacturer))
                      (PRN (-LRB- -LRB-)
                        (NP (NN NE) (NN Biolabs))
                        (-RRB- -RRB-))))))))))
      (CC and)
      (S
        (NP (JJ complete) (NN methylation))
        (VP (VBD was)
          (VP (VBN checked)
            (PP (IN via)
              (NP
                (NP (NN restriction) (NN analysis))
                (PRN (-LRB- -LRB-)
                  (NP (NN Figure) (NN 5A))
                  (-RRB- -RRB-))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Reporter) (NN gene) (NNS assays))
        (VP (VBG using)
          (NP
            (NP (DT the) (JJ dual) (NN luciferase) (NN assay))
            (PRN (-LRB- -LRB-)
              (NP (NN Promega))
              (-RRB- -RRB-)))))
      (VP (VBD were)
        (VP (VBN performed)
          (ADVP (JJ similar)
            (PP (TO to)
              (NP (JJ previous) (NNS reports)))
            (PRN (-LRB- -LRB-)
              (NP (CD 29))
              (-RRB- -RRB-))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Briefly))
      (, ,)
      (NP
        (NP (CD 5) (NN nM))
        (PP (IN of)
          (NP (DT the)
            (NP (NN reporter) (NN construct))
            (CC and)
            (NP
              (NP (DT the) (NN transfection) (NN control) (NN construct))
              (VP (VBG expressing)
                (NP (DT the) (NN renilla) (NN luciferase) (NN gene)))))))
      (VP (VBD were)
        (VP (VBN transientlyco-expressed)
          (PP (IN via)
            (NP (NN electroporation))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NN control) (NN construct))
      (VP (VBD served)
        (PP (IN as)
          (NP
            (NP (DT an) (JJ internal) (NN reference))
            (PP (IN for)
              (NP (NN transfection) (NN efficiency)))))))
    (. .)))

(
  (S
    (S
      (PP
        (NP (CD Forty-eight) (NNS hours))
        (IN after)
        (NP (NN transfection)))
      (, ,)
      (NP (NN luciferase) (NN activity))
      (VP (VBD was)
        (VP (VBN measured)
          (PP (IN with)
            (NP
              (NP (DT a) (NN LB) (CD 96) (NN P) (NN microlumat))
              (PRN (-LRB- -LRB-)
                (NP
                  (NP
                    (NP (NNP EG&G) (NNP Berthold))
                    (, ,)
                    (NP (NN Bad)))
                  (NP (NNP Wildbad) (, ,) (NNP Germany)))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (S
      (NP (NN IRF-4) (NN promoter) (NN activation))
      (VP (VBD was)
        (VP (VBN quantified)
          (PP (IN as)
            (NP
              (NP (DT a) (NN ratio))
              (PP (IN of)
                (NP
                  (NP (VBN measured) (JJ firefly) (JJ light) (NNS units))
                  (PRN (-LRB- -LRB-)
                    (NP (NN flu))
                    (-RRB- -RRB-))))
              (PP (JJ relative) (TO to)
                (NP
                  (NP (NN renilla))
                  (PRN (-LRB- -LRB-)
                    (NP (NN rlu))
                    (-RRB- -RRB-)))))))))
    (. .)))

(
  (S
    (S
      (NP (DT Each) (NN experiment))
      (VP (VBD was)
        (VP (VBN carried)
          (PRT (RP out))
          (NP
            (QP (IN at) (JJS least) (CD three))
            (NNS times)))))
    (. .)))

(
  (S
    (NP (NNS RESULTS))))

(
  (S
    (S
      (NP (PRP We))
      (VP (VBP have)
        (ADVP (RB previously))
        (VP (VBN demonstrated)
          (NP
            (NP (DT a) (NN lack))
            (PP (IN of)
              (NP
                (NP (NN IRF-4) (NN expression))
                (PP
                  (PP (IN in)
                    (NP (NN leukemia) (NNS patients)))
                  (CC and)
                  (ADVP (RB specifically))
                  (PP (IN in)
                    (NP
                      (NP (NN CML) (NNS T-cells))
                      (PRN (-LRB- -LRB-)
                        (NP (CD 3))
                        (-RRB- -RRB-)))))))))))
    (. .)))

(
  (S
    (ADVP (RB Here))
    (, ,)
    (NP (PRP we))
    (VP (VBP demonstrate)
      (NP
        (NP (DT the) (NN absence))
        (PP (IN of)
          (NP (NN IRF-4) (NN expression)))
        (PP
          (PP (IN in)
            (NP
              (NP (JJ various) (JJ hematopoietic) (NN cell) (NNS lines))
              (, ,)
              (ADJP (JJ such)
                (PP (IN as)
                  (NP
                    (NP
                      (NP (NN Jurkat))
                      (, ,)
                      (NP (DT a) (NN T-cell) (NN leukemia))
                      (, ,)
                      (NP (NN CML-T1))
                      (, ,)
                      (NP (DT a) (JJ bcr-abl-positive) (NN T-cell) (NN line))
                      (, ,)
                      (NP (NN K-562))
                      (, ,)
                      (NP (DT a) (JJ bcr-abl-positve) (NN erythroleukemia))
                      (, ,)
                      (NP (NN U-937))
                      (, ,)
                      (NP (DT a) (JJ monocytic) (NN leukemia))
                      (, ,)
                      (NP (NN EM-2))
                      (CC and)
                      (NP (CD LAMA-84)))
                    (, ,)
                    (NP (JJ bcr-abl-positve) (JJ myeloid) (NN leukemia)))))
              (, ,)))
          (CC but)
          (PP (RB not) (IN in)
            (NP
              (NP (NN SD-1))
              (, ,)
              (NP
                (NP (DT a) (JJ bcr-abl-positive) (JJ acute) (JJ lymphoblastic) (NN leukemia))
                (PRN (-LRB- -LRB-)
                  (NP (NN pre) (NN B-ALL))
                  (-RRB- -RRB-)))
              (, ,)
              (NP (CD RPMI-8226))
              (, ,)
              (NP (DT a) (JJ multiple) (NN myeloma))
              (CC and)
              (NP
                (NP (NN BV-173))
                (, ,)
                (NP (DT a) (JJ bcr-abl-positive) (NN B-cell) (NN line))))))
        (-LRB- -LRB-)
        (PP (FW Figures)
          (NP
            (NP (NN 1A))
            (CC and)
            (NP (CD 5D) (-RRB- -RRB-))))))
    (. .)))

(
  (S
    (S
      (PP (IN After)
        (NP
          (NP (NN sequencing))
          (PP (IN of)
            (NP (DT the) (NN IRF-4) (NN promoter)))))
      (, ,)
      (NP (PRP it))
      (VP (MD could)
        (VP (VB be)
          (VP (VBN excluded)
            (SBAR (IN that)
              (S
                (NP
                  (NP (NN absence))
                  (PP (IN of)
                    (NP
                      (NP (NN IRF-4) (NN expression))
                      (PP (IN in)
                        (NP
                          (NP (DT any))
                          (PP (IN of)
                            (NP (DT the) (JJ above) (NN cell) (NNS lines))))))))
                (VP (VBD was)
                  (ADJP (JJ due)
                    (PP (TO to)
                      (NP (JJ genetic) (NNS aberrations)))))))))))
    (. .)))

(
  (S
    (ADVP (RB However))
    (, ,)
    (NP
      (NP (CD 2) (NN bp) (NNS changes))
      (PRN (-LRB- -LRB-)
        (NP
          (NP (NN nucleotide) (NN −1081) (, ,) (NNP T→C))
          (CC and)
          (NP (NNP −1068) (, ,) (NNP A→C)))
        (-RRB- -RRB-)))
    (VP (MD could)
      (VP (VB be)
        (VP (VBN detected)
          (PP (IN in)
            (NP (CC both)
              (NP (DT the) (JJ IRF-4-positive) (NN BV-173))
              (CC and)
              (NP
                (NP (DT the) (JJ IRF-4-negative) (NN LAMA-84))
                (, ,)
                (NP
                  (NP
                    (NP (NN EM-2))
                    (CC and)
                    (NP (NN K-562)))
                  (PRN (-LRB- -LRB-)
                    (NP (NN Figure) (NN 1B))
                    (-RRB- -RRB-)))))))))
    (. .)))

(
  (S
    (S
      (PP (IN At)
        (NP (NN position) (CD −116)))
      (NP (DT an) (NN A→C) (NN substitution))
      (VP (VBD was)
        (VP (VBN found)
          (PP (IN in)
            (NP
              (NP (NN EM-2))
              (, ,)
              (NP (NN K-562))
              (CC and)
              (NP (NN CML-T1)))))
        (, ,)
        (SBAR (IN whereas)
          (S
            (NP
              (NP (NN Jurkat))
              (, ,)
              (NP (NN BV-173))
              (CC and)
              (NP (NN SD-1)))
            (VP (VBD exhibited)
              (NP
                (NP (DT a) (JJ mixed) (NN A/C) (NN sequence))
                (CC and)
                (NP
                  (NP
                    (NP (NN U-937))
                    (, ,)
                    (NP (NN LAMA-84))
                    (CC and)
                    (NP
                      (NP (CD RPMI-8226) (NN no) (NN substitution))
                      (PP (IN at)
                        (NP (NN all)))))
                  (PRN (-LRB- -LRB-)
                    (NP (NN Figure) (NN 1B))
                    (-RRB- -RRB-)))))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Consequently))
      (, ,)
      (NP (DT these) (NNS alterations))
      (VP (VBP are)
        (ADJP (JJ unlikely)
          (S
            (VP (TO to)
              (VP (VB affect)
                (NP (NN IRF-4) (NN expression))))))))
    (. .)))

(
  (S
    (S
      (NP (PRP We))
      (ADVP (RB next))
      (VP (VBD analyzed)
        (SBAR (IN whether)
          (S
            (NP (NN promoter) (NN methylation))
            (VP (MD could)
              (VP (VB be)
                (ADJP (JJ responsible)
                  (PP (IN for)
                    (NP
                      (NP (NN down-regulation))
                      (PP (IN of)
                        (NP (NN IRF-4) (NN expression))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT A) (NN region))
        (VP (VBG including)
          (NP
            (NP (NN exon1))
            (PP (IN in)
              (NP (DT the) (NN IRF-4) (NN promoter))))))
      (VP (VBD exhibited)
        (NP
          (NP (DT a) (JJ large) (NN number))
          (PP (IN of)
            (NP
              (NP (JJ CpG-rich) (NNS sequences))
              (PRN (-LRB- -LRB-)
                (NP (NN Figure) (NN 3A))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Several) (JJ chemical) (NNS substances))
        (PP (JJ such) (IN as)
          (NP
            (NP
              (NP (NN 5-aza-2-deoxycytidine))
              (PRN (-LRB- -LRB-)
                (NP (NN AzadC))
                (-RRB- -RRB-)))
            (CC or)
            (NP
              (NP (NN 5-azacytidine))
              (PRN (-LRB- -LRB-)
                (NP (NN AzaC))
                (-RRB- -RRB-))))))
      (VP (VBP inhibit)
        (NP
          (NP (FW de) (FW novo))
          (CC and)
          (NP (NN maintenance) (NN methylation)))))
    (, ,)
    (CC and)
    (S
      (ADVP (RB thus))
      (VP (MD can)
        (VP (VB be)
          (VP (VBN used)
            (S
              (VP (TO to)
                (VP (VB discern)
                  (NP
                    (NP (NN promoter) (NN methylation))
                    (PRN (-LRB- -LRB-)
                      (NP (NN 32,33))
                      (-RRB- -RRB-))))))))))
    (. .)))

(
  (S
    (S
      (NP (PRP We))
      (VP (VBD used)
        (NP (NN AzadC))
        (S
          (VP (TO to)
            (VP (VB generate)
              (NP (JJ unmethylated) (NN DNA)))))))
    (. .)))

(
  (S
    (S
      (NP (DT A)
        (ADJP (CD 72) (NN h))
        (NN AzadC-treatment))
      (VP (VBD resulted)
        (PP
          (PP (IN in)
            (NP
              (NP (DT a) (JJ concentration-dependent) (NN activation))
              (PP (IN of)
                (NP (NN IRF-4) (NN transcription)))
              (PP (IN in)
                (NP (NN Jurkat)
                  (CC and)
                  (NN CML-T1) (NNS T-cells)))))
          (CONJP (RB as) (RB well) (IN as))
          (PP (IN in)
            (NP
              (NP
                (NP
                  (NP (NN U-937))
                  (, ,)
                  (NP (NN K-562))
                  (CC and)
                  (NP (NN EM-2)))
                (NN cell) (NNS lines))
              (PRN (-LRB- -LRB-)
                (NP (NN Figure) (NN 2A))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (S
      (NP (NN IRF-4) (NN transcription))
      (VP
        (VP (VBD was)
          (VP (VBN induced)
            (PP (IN in)
              (NP (DT a) (JJ time-dependent) (NN manner)))))
        (CC and)
        (VP (VBD was)
          (VP (VBN observed)
            (ADVP (RB as) (RB early))
            (PP (IN as)
              (NP (CD 24) (NN h)))
            (PP (IN after)
              (NP
                (NP (NN treatment))
                (PP (IN with)
                  (NP (NN AzadC)))))))
        (CC and)
        (VP (VBD increased)
          (PP (IN over)
            (NP (NN time)))
          (PP (IN until)
            (NP
              (NP (CD 72) (NN h))
              (PRN (-LRB- -LRB-)
                (NP (NN Figure) (NN 2B))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP
          (NP (NN Time))
          (CC and)
          (NP (NN strength)))
        (PP (IN of)
          (NP
            (NP (DT the) (NN appearance))
            (PP (IN of)
              (NP (NN IRF-4) (NNS transcripts))))))
      (VP (VBD varied)
        (PP (IN among)
          (NP (NN cell) (NNS lines)))
        (, ,)
        (PP (FW i.e.))))
    (. .)))

(
  (S
    (S
      (NP (NN CML-T1))
      (VP (VBD responded)
        (ADVP (JJS strongest))
        (PP (TO to)
          (NP (NN AzadC-treatment)))
        (PRN (-LRB- -LRB-)
          (S
            (NP (NNS data))
            (VP (RB not) (VBN shown)))
          (-RRB- -RRB-))))
    (. .)))

(
  (S
    (PP (IN In)
      (NP
        (NP (NN line))
        (PP (IN with)
          (NP (DT this)))))
    (, ,)
    (NP
      (NP (NN AzadC-treatment))
      (PP (IN of)
        (NP
          (NP (NN CML-T1))
          (CC and)
          (NP (NN LAMA-84) (NNS cells)))))
    (ADVP (RB also))
    (VP (VBN translated)
      (PP (IN in)
        (NP
          (NP (DT an) (NN induction))
          (PP (IN of)
            (NP
              (NP (NN IRF-4) (NN protein) (NN expression))
              (PRN (-LRB- -LRB-)
                (NP (NN Figure) (NN 2C))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (ADVP (RB Accordingly))
    (, ,)
    (NP
      (NP (NN treatment))
      (PP (IN of)
        (NP
          (NP (DT the) (JJ IRF-4-positive) (NN cell) (NN line) (CD BV-173))
          (, ,)
          (NP
            (NP (NN SD-1))
            (CC and)
            (NP (NN RPMI-8226)))))
      (PP (IN with)
        (NP (NN AzadC))))
    (VP (VBD had)
      (NP (DT no) (NN effect))
      (PP (IN on)
        (NP
          (NP (NN IRF-4) (NN expression))
          (PRN (-LRB- -LRB-)
            (NP (NN Figure) (NN 2D))
            (-RRB- -RRB-)))))
    (. .)))

(
  (S
    (S
      (NP (EX There))
      (VP (VBD was)
        (NP (DT no) (NN difference))
        (PP (IN in)
          (NP
            (NP (DT the) (NNS effects))
            (PP (IN of)
              (NP
                (NP (NNP AzaC))
                (CC versus)
                (NP (NNP AzadC))))))
        (, ,)
        (SBAR (IN as)
          (S
            (NP (DT both))
            (VP (VBD increased)
              (NP
                (NP (DT the) (NN IRF-4) (NN mRNA) (NN level))
                (PP (IN in)
                  (NP (NN CML-T1) (NNS cells))))
              (PP (IN as)
                (NP (NN well)))
              (PRN (-LRB- -LRB-)
                (S
                  (NP (NNS data))
                  (VP (RB not) (VBN shown)))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (S
      (NP (DT This))
      (VP (VBD implied)
        (SBAR (IN that)
          (S
            (S
              (NP (NN promoter) (NN methylation))
              (VP (MD may)
                (VP (VB control)
                  (NP (NN IRF-4) (NN expression)))))
            (, ,)
            (CC but)
            (S
              (NP (DT an) (JJ alternative) (NN explanation))
              (VP (MD may)
                (VP (VB be)
                  (NP
                    (NP (NN activation))
                    (PP (IN of)
                      (NP
                        (NP (JJ positive) (JJ transcriptional) (NNS regulators))
                        (PP (IN of)
                          (NP (NN IRF-4)))))
                    (PP (IN by)
                      (NP
                        (NP (NNP AzadC))
                        (-LRB- -LRB-)
                        (CC or)
                        (NP (NNP AzaC))
                        (-RRB- -RRB-)))))))))))
    (. .)))

(
  (S
    (S
      (S
        (VP (TO To)
          (ADVP (RB further))
          (VP (VB investigate)
            (NP (NN promoter) (NN methylation))
            (PP (IN as)
              (NP
                (NP (DT a) (JJ regulatory) (NN mechanism))
                (PP (IN of)
                  (NP (NN IRF-4) (NN gene) (NN expression))))))))
      (, ,)
      (NP (NNS restriction-PCR-assays))
      (VP (VBD were)
        (VP (VBN performed)
          (PRN (-LRB- -LRB-)
            (NP (NN 20,24))
            (-RRB- -RRB-)))
        (, ,)
        (SBAR
          (WHADVP (WRB where))
          (S
            (NP (RB only) (VBN methylated) (NN DNA))
            (VP (MD would) (RB not)
              (VP (VB be)
                (VP (VBN cut)
                  (S
                    (VP (VBG enabling)
                      (NP
                        (NP (JJ subsequent) (NN PCR) (NN amplification))
                        (CC and)
                        (NP (RB vice) (RB versa))))))))))))
    (. .)))

(
  (S
    (NP
      (NP (JJ Genomic) (NN DNA))
      (PP (IN from)
        (NP
          (NP (JJ leukemic) (NNS cells)
            (NP
              (NP (NN Jurkat))
              (, ,)
              (NP (NN CML-T1))))
          (, ,)
          (NP
            (NP (NN U-937))
            (, ,)
            (NP (NN K-562))
            (, ,)
            (NP (NN EM-2))
            (CC and)
            (NP (NN BV-173))))))
    (VP (VBD was)
      (VP (VBN digested)
        (PP (IN with)
          (NP
            (NP (DT the) (JJ methylation-sensitive) (NNS enzymes))
            (NP
              (NP (NN HpaII))
              (, ,)
              (NP (NN Bsh1236I))
              (CC and)
              (NP (NN HaeII-isochizomer) (NN Bsp143II)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP
          (NP (NN EcoRI))
          (, ,)
          (SBAR
            (WHNP (WDT which))
            (S
              (VP (VBZ has)
                (NP
                  (NP (DT no) (NN recognition) (NN site))
                  (PP (IN within)
                    (NP (DT the) (NN IRF-4) (NN promoter)))))))
          (, ,))
        (CC and)
        (NP (DT the) (JJ methylation-resistant) (NN enzyme) (NN MspI)))
      (VP (VBD served)
        (PP (IN as)
          (NP (NNS controls)))))
    (. .)))

(
  (S
    (S
      (NP (CD Two) (JJ separate) (NN amplification) (NNS reactions))
      (VP (VBD were)
        (VP (VBN performed) (, ,)
          (S
            (VP (VBG generating)
              (NP
                (NP (CD two) (NNS fragments))
                (, ,)
                (NP
                  (NP
                    (NP (NN F1))
                    (CC and)
                    (NP (NN F2)))
                  (PRN (-LRB- -LRB-)
                    (NP (NN Figure) (NN 3A))
                    (-RRB- -RRB-)))))))))
    (. .)))

(
  (S
    (S
      (PP (IN After)
        (NP
          (NP (NN digestion))
          (PP (IN with)
            (NP
              (NP (NN HpaII))
              (CC and)
              (NP (NN Bsp143II))))))
      (NP
        (NP (DT a) (JJ sufficient) (NN PCR) (NN amplification))
        (PP (IN of)
          (NP
            (NP (NN F1))
            (CC and)
            (NP (NN F2)))))
      (VP (VBD was)
        (VP (VBN detected)
          (PP (IN in)
            (NP
              (NP (NN DNA))
              (PP (IN from)
                (NP (JJ IRF-4-negative) (NN Jurkat) (, ,) (NN CML-T1) (, ,) (NN U-937) (, ,) (NN K-562)
                  (CC and)
                  (NN EM-2) (NNS cells)))))
          (, ,)
          (S
            (VP (VBG suggesting)
              (NP
                (NP
                  (NP (DT a) (NN promoter) (NN methylation))
                  (-LRB- -LRB-)
                  (CC and)
                  (NP (NN restriction) (NN protection))
                  (-RRB- -RRB-))
                (PP (IN at)
                  (NP
                    (NP (DT the) (JJ respective) (NN recognition) (NNS sites))
                    (PRN (-LRB- -LRB-)
                      (NP
                        (NP (NN Figure) (NN 3B))
                        (CC and)
                        (NP (NN C)))
                      (-RRB- -RRB-))))))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Notably))
      (, ,)
      (PP (IN in)
        (NP (JJ IRF-4-positive) (NN SD-1) (NNS cells)))
      (NP
        (NP (NN digestion))
        (PP (IN with)
          (NP (DT the) (JJ methylation-sensitive) (NNS enzymes))))
      (ADVP (RB completely))
      (VP (VBD inhibited)
        (NP
          (NP (NN amplification))
          (PP (IN of)
            (NP
              (NP (NN F1))
              (CC and)
              (NP (NN F2)))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (JJ IRF-4-positive) (NN BV-173) (NNS cells)))
      (NP
        (NP (DT a) (NN HpaII))
        (, ,)
        (CONJP (CC but)
          (RB not))
        (NP (DT a) (NN Bsh1236I) (NN digestion))
        (, ,))
      (ADVP (RB significantly))
      (VP (VBD reduced)
        (NP
          (NP (DT the) (NN amplifiable) (NN DNA) (NN message))
          (PP (IN of)
            (NP
              (NP (NN F2))
              (PRN (-LRB- -LRB-)
                (NP (NN Figure) (NN 3C))
                (-RRB- -RRB-)))))
        (, ,)
        (SBAR (IN whereas)
          (S
            (NP
              (NP (NN amplification))
              (PP (IN of)
                (NP (NN F1))))
            (VP (VBD was) (RB not)
              (VP (VBN affected)
                (PRN (-LRB- -LRB-)
                  (NP (NN Figure) (NN 3B))
                  (-RRB- -RRB-))))))))
    (. .)))

(
  (S
    (S
      (NP (DT This))
      (VP (VBD implied)
        (SBAR (IN that)
          (S
            (NP
              (NP (NN IRF-4) (NN transcription))
              (PP (IN in)
                (NP
                  (QP (CD SD-1)
                    (CC and)
                    (CD BV-173))
                  (NNS cells))))
            (VP (VBZ is)
              (VP (VBN associated)
                (PP (IN with)
                  (NP
                    (NP (RBR less) (NN promoter) (NN methylation))
                    (PRN (-LRB- -LRB-)
                      (PP (IN in)
                        (NP
                          (NP (CD BV-173))
                          (ADVP (RB especially)
                            (PP (IN at)
                              (NP (NN HpaII) (NNS sites))))))
                      (-RRB- -RRB-))))
                (SBAR (IN as)
                  (S
                    (VP (VBN compared)
                      (PP (IN with)
                        (NP (DT the) (VBN tested) (JJ IRF-4-negative) (NNS cells))))))))))))
    (. .)))

(
  (S
    (PP (IN In)
      (NP
        (NP (NN order))
        (VP (TO to)
          (ADVP (RB exactly))
          (VP (VB map)
            (NP
              (NP (DT the) (NN methylation) (NNS sites))
              (PP (IN within)
                (NP (DT the) (NN IRF-4) (NN promoter))))))))
    (, ,)
    (NP (PRP we))
    (VP (VBD treated)
      (NP
        (NP (NN DNA))
        (PP
          (PP (IN of)
            (NP (NN Jurkat) (, ,) (NN CML-T1) (, ,) (NN U-937) (, ,) (NN K-562)
              (CC and)
              (NN EM-2) (NNS cells)))
          (CONJP (RB as) (RB well) (IN as))
          (PP (IN of)
            (NP
              (QP (CD SD-1) (, ,) (CD RPMI-8226)
                (CC and)
                (CD BV-173))
              (NN control) (NNS cells)))))
      (PP (IN with)
        (NP
          (NP (NN bisulfite))
          (, ,)
          (SBAR
            (WHNP (WDT which))
            (S
              (ADVP (RB chemically))
              (VP (VBZ converts)
                (NP (JJ unmethylated) (NN cytosine))
                (PP (TO to)
                  (NP (NN uracil))))))))
      (, ,)
      (SBAR (IN whereas)
        (S
          (NP (PRP it))
          (VP (VBZ has)
            (NP (DT no) (NN effect))
            (PP
              (PP (IN on)
                (NP (VBN methylated) (NN cytosine)))
              (, ,) (FW i.e.)
              (PP (IN in)
                (NP (NN CpG) (-LRB- -LRB-) (CD 34) (-RRB- -RRB-))))))))
    (. .)))

(
  (S
    (S
      (NP (DT This) (NN technique))
      (VP (VBZ is)
        (ADJP (RB especially) (JJ useful)
          (PP (IN for)
            (NP
              (NP (NN detection))
              (PP (IN of)
                (NP (JJ unknown) (NN methylation) (NNS patterns))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP
          (NP (NN PCR) (NN amplification))
          (, ,)
          (NP (NN cloning))
          (CC and)
          (NP (NN sequencing)))
        (PP (IN of)
          (NP (DT the) (JJ bisulfite-treated) (NN DNA))))
      (VP (VBD showed)
        (NP
          (NP (DT a) (JJ specific) (NN methylation) (NN pattern))
          (PP (IN of)
            (NP (DT the) (VBN analyzed) (CD 62) (NN CpG) (NNS sites))))
        (PP (IN in)
          (NP
            (NP (DT all) (NN cell) (NNS lines))
            (PRN (-LRB- -LRB-)
              (NP
                (NP (NN Figure) (CD 4))
                (CC and)
                (NP (NN Table) (CD 1)))
              (-RRB- -RRB-))))))
    (. .)))

(
  (S
    (PP (IN In)
      (NP (JJ general)))
    (, ,)
    (NP (DT the) (JJ methylational) (NN status))
    (VP (VBD ranged)
      (PP (IN from)
        (NP
          (NP (CD one) (NN cell) (NN line))
          (PP (IN with)
            (NP
              (NP (DT a) (RB nearly) (JJ non-methylated) (NN IRF-4) (NN promoter))
              (PRN (-LRB- -LRB-)
                (NP
                  (NP (NN SD-1))
                  (, ,)
                  (NP (NN IRF-4-positive)))
                (-RRB- -RRB-))))))
      (PP (TO to)
        (NP
          (NP (DT a)
            (ADJP (RB completely) (VBN methylated))
            (NN IRF-4) (NN promoter))
          (PP (IN in)
            (NP
              (NP (NN CML-T1))
              (PRN (-LRB- -LRB-)
                (NP (NN IRF-4-negative))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Interestingly))
      (, ,)
      (NP
        (NP (DT the) (NN percentage))
        (PP (IN of)
          (NP (NN CpG) (NN methylation)))
        (PP (IN in)
          (NP
            (NP (DT the) (NN IRF-4) (NN promoter))
            (PP (IN from)
              (NP (JJ IRF-4-positive) (NNS cells))))))
      (VP (VBD was)
        (ADJP (RB very) (JJ low)
          (PRN (-LRB- -LRB-)
            (NP (NN mean) (CD 24) (NN %))
            (-RRB- -RRB-)))
        (SBAR (IN as)
          (S
            (VP (VBN compared)
              (PP (IN with)
                (NP
                  (NP
                    (NP (JJ IRF-4-negative) (NNS cells))
                    (PRN (-LRB- -LRB-)
                      (NP (NN mean) (CD 94) (NN %))
                      (-RRB- -RRB-)))
                  (PRN (-LRB- -LRB-)
                    (NP
                      (NP (NN Figure) (NN 4A))
                      (CC and)
                      (NP (NN Table) (CD 1)))
                    (-RRB- -RRB-)))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP
          (NP (DT A) (NN 5′-region))
          (PRN (-LRB- -LRB-)
            (NP (NN R1))
            (-RRB- -RRB-)))
        (PP (IN with)
          (NP
            (NP (CD 13) (JJ hypermethylated) (NN CpG) (NNS sites))
            (PRN (-LRB- -LRB-)
              (NP
                (NP (NN mean) (NN number))
                (PP (IN of)
                  (NP
                    (NP (VBN methylated) (NNS clones)
                      (NP (CD 5.5)))
                    (PP (IN of)
                      (NP
                        (ADJP
                          (NP
                            (QP (CD 8) (IN with) (CD 77))
                            (NN %))
                          (VBN methylated))
                        (NNS CpGs))))))
              (-RRB- -RRB-)))))
      (VP (VBD was)
        (VP (VBN found)
          (PP (IN in)
            (NP (JJS most) (NNS cells)))
          (PRN (-LRB- -LRB-)
            (QP (IN except) (CD SD-1)
              (CC and)
              (CD RPMI-8226))
            (-RRB- -RRB-)))))
    (CC and)
    (S
      (NP
        (NP
          (NP (DT a) (NN 3′-region))
          (PRN (-LRB- -LRB-)
            (NP (NN R3))
            (-RRB- -RRB-)))
        (PP (IN of)
          (NP
            (NP (CD 6) (VBN hypomethylated) (NN CpG) (NNS sites))
            (PRN (-LRB- -LRB-)
              (NP
                (NP
                  (NP
                    (NP (NN mean) (NN number))
                    (PP (IN of)
                      (NP (VBN methylated) (NNS clones))))
                  (NP
                    (QP (CD 1.7) (IN of) (CD 8))
                    (PP (IN with)
                      (NP (CD 33) (NN %)))))
                (VBN methylated) (NNS CpGs))
              (-RRB- -RRB-)))))
      (VP (VBD was)
        (VP (VBN found)
          (PP (IN in)
            (NP
              (NP
                (NP (JJS most) (NNS cells))
                (PRN (-LRB- -LRB-)
                  (PP (IN except)
                    (NP
                      (NP (NN CML-T1))
                      (CC and)
                      (NP (NN U-937))))
                  (-RRB- -RRB-)))
              (PRN (-LRB- -LRB-)
                (NP
                  (NP (NN Figure) (NN 4A))
                  (CC and)
                  (NP (NN Table) (CD 1)))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (ADVP (RB Intriguingly))
    (, ,)
    (NP
      (NP (DT a) (NN stretch))
      (PP (IN of)
        (NP
          (NP (CD 13) (NN CpG) (NNS sites))
          (PRN (-LRB- -LRB-)
            (NP
              (NP (NN #) (NN 10–22))
              (: ;)
              (NP (NN R2)))
            (-RRB- -RRB-)))))
    (VP (VBD was)
      (VP (VBN detected)
        (PP (IN in)
          (PP (IN between)
            (NP
              (NP (DT these) (NNS regions))
              (, ,)
              (SBAR
                (WHNP (WDT which))
                (S
                  (VP (VBD were)
                    (UCP
                      (VP
                        (ADVP (RB highly))
                        (VBN methylated)
                        (PP (IN in)
                          (NP
                            (NP (JJ IRF-4-negative))
                            (PRN (-LRB- -LRB-)
                              (NP
                                (NP (NN mean) (NN number))
                                (PP (IN of)
                                  (NP (VBN methylated) (NNS clones))))
                              (QP (CD 7.1) (IN of) (CD 8))
                              (PP (IN with)
                                (NP
                                  (ADJP
                                    (NP (CD 89) (NN %))
                                    (VBN methylated))
                                  (NNS CpGs)))
                              (-RRB- -RRB-)))))
                      (CC but)
                      (ADJP (RB totally) (JJ non-methylated)
                        (PP (IN in)
                          (NP
                            (NP (JJ IRF-4-positive) (NNS cells))
                            (PRN (-LRB- -LRB-)
                              (NP
                                (NP (NN Figure) (NN 4A))
                                (CC and)
                                (NP (NN B)))
                              (-RRB- -RRB-))))))))))))))
    (. .)))

(
  (S
    (ADVP (RB Furthermore))
    (, ,)
    (NP
      (NP
        (NP (CD three) (NN CpG) (NNS sites))
        (PP (IN at)
          (NP
            (NP (DT the) (JJ 5′) (NN end))
            (PRN (-LRB- -LRB-)
              (NP
                (NP (NNP #) (CD 54) (, ,) (CD 56))
                (, ,)
                (NP (CD 58)))
              (-RRB- -RRB-)))))
      (CC and)
      (NP
        (NP (CD two) (NN CpG) (NNS motifs))
        (PP (IN at)
          (NP
            (NP (DT the) (JJ 3′) (NN end))
            (PRN (-LRB- -LRB-)
              (NP (NN #) (CD 1) (, ,) (CD 2))
              (-RRB- -RRB-))))))
    (VP (VBD showed)
      (NP
        (NP (DT this) (JJ direct) (NN correlation))
        (PP (IN between)
          (NP
            (NP
              (NP (JJ high) (NN methylation) (NN status))
              (CC and)
              (NP (NN absence)))
            (PP (IN of)
              (NP (NN IRF-4) (NN expression)))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (NN addition)))
      (, ,)
      (NP
        (NP (CD two) (NN CpG) (NNS sites))
        (ADJP (JJ located)
          (PP (IN in)
            (NP
              (NP
                (NP (DT a) (NN NFκB))
                (PRN (-LRB- -LRB-)
                  (NP (NN #) (CD 48))
                  (-RRB- -RRB-)))
              (CC and)
              (NP
                (NP (DT a) (NN SP1) (NN element))
                (PRN (-LRB- -LRB-)
                  (NP (NN #) (CD 45))
                  (-RRB- -RRB-)))))))
      (VP (VBP are)
        (ADJP (RBR less) (VBN methylated)
          (PP (IN in)
            (NP (NN IRF-4-positive)))
          (PP (IN than)
            (PP (IN in)
              (NP
                (NP (JJ IRF-4-negative) (NNS cells))
                (PRN (-LRB- -LRB-)
                  (NP
                    (NP (NN mean) (NN number))
                    (PP (IN of)
                      (NP (VBN methylated) (NNS clones))))
                  (: :)
                  (QP (CD 1/8)
                    (CC versus)
                    (CD 8/8))
                  (-RRB- -RRB-))))))))
    (. .)))

(
  (S
    (S
      (NP (DT These) (NNS results))
      (VP (VBP indicate)
        (NP
          (NP (DT the) (NN involvement))
          (PP (IN of)
            (NP (NN CpG) (NN methylation)))
          (PP (IN in)
            (NP
              (NP (DT the) (NN regulation))
              (PP (IN of)
                (NP
                  (NP (NN IRF-4) (NN expression))
                  (PP (IN in)
                    (NP (JJ leukemic) (NNS cells))))))))))
    (. .)))

(
  (S
    (S
      (S
        (VP (TO To)
          (VP (VB provide)
            (NP
              (NP (NN evidence))
              (PP (IN for)
                (NP
                  (NP (DT a) (JJ direct) (NN effect))
                  (PP (IN of)
                    (NP (JJ methylational) (NN status)))
                  (PP (IN on)
                    (NP (NN IRF-4) (NN promoter) (NN activity)))))))))
      (NP (PRP we))
      (VP (VBD performed)
        (NP (NN reporter) (NN gene) (NNS assays))
        (PP (IN with)
          (NP
            (NP (NN IRF-4) (NN promoter) (NNS constructs))
            (PP
              (PP (IN before))
              (CC and)
              (PP (IN after)
                (NP (PRP$ their)
                  (ADJP (FW in) (FW vitro))
                  (NN methylation))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT A) (JJ complete) (NN methylation))
        (PP (IN of)
          (NP (DT these) (NNS constructs))))
      (VP (VBD was)
        (VP (VBN checked)
          (PP (IN via)
            (NP
              (NP (NN restriction) (NNS assays))
              (PP (IN with)
                (NP
                  (NP (JJ methylation-sensitive) (NNS endonucleases))
                  (PRN (-LRB- -LRB-)
                    (NP (NN Figure) (NN 5A))
                    (-RRB- -RRB-)))))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Intriguingly))
      (, ,)
      (NP
        (NP (NN methylation))
        (PP (IN of)
          (NP (DT the) (NN IRF-4) (NN promoter))))
      (ADVP (RB significantly))
      (VP (VBD decreased)
        (NP (NN promoter) (NN activity))
        (PP (IN in)
          (NP (JJ IRF-4-positive) (NN SD-1) (NNS cells)))
        (PP (IN by)
          (NP
            (NP (CD 85.0) (NN %))
            (PRN (-LRB- -LRB-)
              (NP (NN Figure) (NN 5B))
              (-RRB- -RRB-))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (JJ silencing) (NN effect))
        (PP (IN of)
          (NP (NN CpG) (NN methylation))))
      (VP (VBD was) (RB not)
        (ADJP (JJ restricted)
          (PP (TO to)
            (NP (JJ IRF-4-positive) (NNS cells))))
        (, ,)
        (SBAR (IN since)
          (S
            (NP
              (ADJP (FW in) (FW vitro))
              (NN methylation))
            (VP (VBD led)
              (PP (TO to)
                (NP
                  (NP (DT a)
                    (ADJP (CD 92.9) (NN %))
                    (NN abrogation))
                  (PP (IN of)
                    (NP (NN promoter) (NN activity)))
                  (PP (IN in)
                    (NP
                      (NP (JJ IRF-4-negative) (NN Jurkat) (NNS cells))
                      (PRN (-LRB- -LRB-)
                        (NP (NN Figure) (NN 5C))
                        (-RRB- -RRB-)))))))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (NN contrast)))
      (, ,)
      (NP
        (NP (NN control) (NN methylation))
        (PP (IN of)
          (NP
            (NP (DT a) (NN reporter) (NN construct))
            (PP (IN with)
              (NP
                (NP
                  (NP (DT a) (JJ different) (NN promoter))
                  (PRN (-LRB- -LRB-)
                    (NP (NN FasL))
                    (-RRB- -RRB-)))
                (CONJP (RB as) (RB well) (IN as))
                (NP (DT an) (JJ empty) (NN vector)))))))
      (VP (VBD had)
        (NP (DT no) (NN effect))
        (PP (IN on)
          (NP
            (NP (DT the) (NN reporter) (NN activity))
            (PRN (-LRB- -LRB-)
              (S
                (NP (NNS data))
                (VP (RB not) (VBN shown)))
              (-RRB- -RRB-))))))
    (. .)))

(
  (S
    (S
      (NP (DT These) (NNS data))
      (VP (VBD proved)
        (NP
          (NP (DT a) (JJ direct) (NN association))
          (PP (IN between)
            (NP
              (NP
                (NP (NN methylation))
                (CC and)
                (NP (NN activity)))
              (PP (IN of)
                (NP (DT the) (NN IRF-4) (NN promoter))))))))
    (. .)))

(
  (S
    (S
      (SBAR (IN Since)
        (S
          (NP
            (NP (NN abundance))
            (PP (IN of)
              (NP
                (NP (NN DNMT))
                (CC and)
                (NP (NN MBP)))))
          (VP (VBP contribute)
            (PP (TO to)
              (NP
                (NP (NN promoter) (NN regulation))
                (PP (IN via)
                  (NP
                    (NP (NN methylation))
                    (PRN (-LRB- -LRB-)
                      (NP (NN 25,26,28))
                      (-RRB- -RRB-)))))))))
      (, ,)
      (NP (PRP we))
      (VP (VBD studied)
        (NP (PRP$ their) (NN mRNA) (NN expression))
        (S
          (VP (TO to)
            (VP (VB investigate)
              (NP
                (NP (DT a) (JJ possible) (NN mechanism))
                (PP (IN for)
                  (NP
                    (NP (DT the) (VBN observed) (NN methylation) (NNS differences))
                    (PP (IN in)
                      (NP (DT the) (NN IRF-4) (NN promoter)))))))))))
    (. .)))

(
  (S
    (S
      (PP (TO To)
        (NP (DT this) (NN end)))
      (, ,)
      (NP (PRP we))
      (VP (VBD did) (RB not)
        (VP (VB detect)
          (NP
            (NP (DT a) (JJ significant) (NN difference))
            (PP (IN in)
              (NP
                (NP (NN DNMT))
                (PRN (-LRB- -LRB-)
                  (NP
                    (NP (NN DNMT1))
                    (, ,)
                    (NP (NN DNMT3A))
                    (CC and)
                    (NP (NN DNMT3B)))
                  (-RRB- -RRB-))
                (CC or)
                (NN MBP)
                (PRN (-LRB- -LRB-)
                  (NP
                    (NP (NN MBD1))
                    (, ,)
                    (NP (NN MBD2))
                    (, ,)
                    (NP (NN MBD4))
                    (CC and)
                    (NP (NN MeCP)))
                  (-RRB- -RRB-))
                (NN mRNA) (NN expression)))
            (PP (IN between)
              (NP
                (NP
                  (ADJP
                    (ADJP (JJ IRF-4-positive))
                    (CC and)
                    (ADJP (JJ -negative)))
                  (NNS cells))
                (PRN (-LRB- -LRB-)
                  (NP (NN Figure) (CD 5D))
                  (-RRB- -RRB-))))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (NN fact)))
      (, ,)
      (S
        (NP (DT all) (VBN analyzed) (NNS cells))
        (VP (VBD had)
          (NP
            (NP (JJ moderate) (TO to) (JJ high) (NN mRNA) (NNS levels))
            (PP (IN of)
              (NP (DT these) (VBN tested) (NNS DNMT/MBPs))))))
      (CC and)
      (S
        (NP
          (NP (NNS differences))
          (PP (IN in)
            (NP (NN expression))))
        (VP (VBD were) (RB not)
          (VP (VBN correlated)
            (PP (IN with)
              (NP (NN IRF-4) (NN status)))))))
    (. .)))

(
  (S
    (S
      (NP (DT These) (NNS results))
      (VP (VBP indicate)
        (NP
          (NP (DT a) (JJ distinct) (NN cause))
          (PP (IN of)
            (NP
              (NP
                (NP (DT the) (NN methylation) (NNS differences))
                (PP (IN in)
                  (NP
                    (ADJP
                      (ADJP (JJ IRF-4-positive))
                      (CC and)
                      (ADJP (JJ -negative)))
                    (NNS cells))))
              (CONJP (RB rather) (IN than))
              (NP
                (NP (NNS changes))
                (PP (IN in)
                  (NP (DT the) (NN DNMT)
                    (CC and)
                    (NN MBP) (NN mRNA) (NN transcription)))))))))
    (. .)))

(
  (S
    (NP (NN DISCUSSION))))

(
  (S
    (S
      (NP (JJ Many) (JJ genetic) (NNS lesions))
      (VP (VBP are)
        (VP (VBN known)
          (S
            (VP (TO to)
              (VP (VB influence)
                (NP
                  (NP (NN gene) (NN expression))
                  (PP (IN of)
                    (NP (NN tumor) (NN suppressor) (NNS genes))))))))))
    (. .)))

(
  (S
    (S
      (SBAR (IN Whereas)
        (S
          (NP
            (NP (NNS mutations))
            (CC and)
            (NP
              (NP (NNS deletions))
              (CC or)
              (NP (NNS insertions))))
          (VP (VBP have)
            (NP (JJ permanent) (NNS effects)))))
      (, ,)
      (NP (JJ reversible) (NNS mechanisms))
      (VP (VBP are)
        (NP
          (NP (NN gene) (NN methylation))
          (, ,)
          (CC or)
          (NP
            (NP
              (NP (NN expression))
              (CC and)
              (NP (NN activation)))
            (PP (IN of)
              (NP (NN transcription) (NNS factors)))))
        (, ,)
        (ADVP (RB respectively))))
    (. .)))

(
  (S
    (S
      (NP (PRP We))
      (VP
        (VP (VBD studied)
          (NP
            (NP (DT a) (JJ putative) (NN cause))
            (PP (IN for)
              (NP
                (NP (JJ absent) (NN IRF-4) (NN expression))
                (PP (IN in)
                  (NP (NN leukemia) (NNS cells)))))))
        (CC and)
        (VP
          (ADVP (RB first))
          (VBD focused)
          (PP (IN on)
            (NP
              (NP (JJ genetic) (NNS aberrations))
              (PP (IN of)
                (NP (DT the) (NN promoter))))))))
    (. .)))

(
  (S
    (S
      (NP (PRP We))
      (VP (VBD observed)
        (NP
          (NP (DT no) (JJ genetic) (NNS alterations))
          (PP (IN in)
            (NP (DT the) (NN IRF-4) (NN promoter)))
          (, ,)
          (SBAR
            (WHNP (WDT which))
            (S
              (VP (MD can)
                (VP (VB account)
                  (PP (IN for)
                    (NP
                      (NP (DT the) (NN lack))
                      (PP (IN of)
                        (NP (NN IRF-4) (NN expression))))))))))))
    (: :)
    (S
      (NP
        (NP (DT The) (VBN detected) (NN base) (NN pair) (NNS changes))
        (PP
          (PP (IN at)
            (NP
              (NP (NN position) (CD −1081))
              (PRN (-LRB- -LRB-)
                (NP (NN T→C) (NN substitution))
                (-RRB- -RRB-))))
          (, ,)
          (PP (IN at)
            (NP
              (NP (NN position) (CD −1068))
              (PRN (-LRB- -LRB-)
                (NP (NN A→C) (NN substitution))
                (-RRB- -RRB-))))
          (CC and)
          (PP (IN at)
            (NP
              (NP (NN position) (CD −116))
              (PRN (-LRB- -LRB-)
                (NP (NN A→C) (NN substitution))
                (-RRB- -RRB-))))))
      (VP (VBP are)
        (ADJP (JJ unlikely))
        (ADJP (JJ responsible)
          (PP (IN for)
            (NP
              (NP (JJ absent) (NN IRF-4-expression))
              (SBAR (IN since)
                (S
                  (NP (DT the) (JJ first) (CD two) (NNS mutations))
                  (VP (VBD were)
                    (VP (VBN found)
                      (PP (CC both)
                        (IN in)
                        (NP
                          (ADJP
                            (ADJP (JJ IRF-4-positive))
                            (CC and)
                            (ADJP (JJ -negative)))
                          (NNS cells)))
                      (PP (IN whereas)
                        (S
                          (NP (DT the) (JJ latter) (NN change))
                          (VP
                            (VP (VBD was) (RB not)
                              (VP (VBN detected)
                                (ADVP (RB consistently))
                                (PP (IN in)
                                  (NP (DT all)
                                    (ADJP
                                      (ADJP (JJ IRF-4-negative))
                                      (CC or)
                                      (ADJP (JJ -positive)))
                                    (NNS cells)))))
                            (CC and)
                            (VP (MD may)
                              (ADVP (RB thus))
                              (VP (VB be)
                                (NP (DT a) (NN polymorphism))))))))))))))))
    (. .)))

(
  (S
    (NP (DT All) (CD three) (NNS substitutions))
    (VP
      (VP (VBD did) (RB not)
        (VP (VB change)
          (NP (DT any) (JJ known) (JJ putative) (NN transcription) (NN factor) (NN binding) (NNS sites))
          (PRN (-LRB- -LRB-)
            (NP (CD 30,31))
            (-RRB- -RRB-))))
      (CC and)
      (ADVP (RB also))
      (VP (VBP do) (RB not)
        (VP (VB affect)
          (NP
            (NP
              (NP (DT any) (NN restriction) (NNS sites))
              (CC or)
              (NP (NN primer) (NN binding) (NNS sites)))
            (PP (IN of)
              (NP (DT the) (VBN used) (NNS assays)))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB However))
      (, ,)
      (NP
        (NP (JJ permanent) (JJ genetic) (NNS variations))
        (PP (IN in)
          (NP (DT the) (NN IRF-4) (NN coding) (NN sequence)))
        (, ,)
        (PP (JJ such) (IN as)
          (NP
            (NP
              (NP (NNS deletions))
              (CC or)
              (NP (NNS mutations)))
            (VP (VBG resulting)
              (PP (IN in)
                (NP (NNS stop-codons)))))))
      (VP (VBP have) (RB not)
        (VP (VBN been)
          (VP (VBN excluded)
            (PP (IN by)
              (NP (NN sequence) (NN analysis)))))))
    (. .)))

(
  (S
    (S
      (SBAR (IN Since)
        (S
          (NP
            (NP (NN IRF-4) (NN expression))
            (PP (IN in)
              (NP
                (NP (NN cell) (NNS lines))
                (CC and)
                (NP (NN CML)))))
          (VP (MD can)
            (VP (VB be)
              (VP (VBN induced)
                (PP (IN by)
                  (NP
                    (NP (NN demethylation))
                    (CC and)
                    (NP
                      (NP (JJ successful) (NN IFN-α) (NN therapy))
                      (PRN (-LRB- -LRB-)
                        (NP (CD 3))
                        (-RRB- -RRB-)))
                    (, ,)
                    (ADVP (RB respectively)))))))))
      (, ,)
      (NP
        (NP (DT the) (NN existence))
        (PP (IN of)
          (NP (JJ such) (JJ genetic) (NNS aberrations))))
      (VP (VBZ seems)
        (ADJP (JJ unlikely))))
    (. .)))

(
  (S
    (S
      (NP (PRP We))
      (ADVP (RB then))
      (VP (VBD investigated)
        (SBAR (IN whether)
          (S
            (NP
              (NP (DT the)
                (ADJP (RB previously) (VBN described))
                (NN down-regulation))
              (PP (IN of)
                (NP (NN IRF-4) (NN expression)))
              (PP (IN in)
                (NP (JJ human) (JJ myeloid) (NNS leukemias))))
            (VP (VBD was)
              (ADJP (JJ due)
                (PP (TO to)
                  (NP
                    (NP (DT a) (JJ differential) (NN hypermethylation))
                    (PP (IN of)
                      (NP (DT the) (NN promoter))))))
              (, ,)
              (SBAR (IN since)
                (S
                  (NP
                    (NP (DT the) (VBN presented) (NN re-expression))
                    (PP (IN due) (TO to)
                      (NP (NN AzadC-treatment))))
                  (VP (MD might)
                    (ADVP (RB also))
                    (VP (VB be)
                      (NP
                        (NP (DT a) (NN result))
                        (PP (IN of)
                          (NP
                            (NP (NN activation))
                            (PP (IN of)
                              (NP
                                (NP (JJ positive) (JJ transcriptional) (NNS regulators))
                                (PP (IN of)
                                  (NP (NN IRF-4)))))))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Methylation))
        (PP (IN of)
          (NP (NN CpG) (NNS sites))))
      (VP
        (VP (VBZ is)
          (NP
            (NP (DT a) (JJ common) (NN mechanism))
            (PP (IN of)
              (NP
                (NP (JJ silencing) (NNS genes))
                (PP (IN in)
                  (NP (NN leukemia)))))))
        (CC and)
        (VP (VBZ has)
          (ADVP (RB also))
          (VP (VBN been)
            (VP (VBN shown)
              (PP
                (PP (IN for)
                  (NP
                    (NP (DT another) (NN IRF))
                    (, ,)
                    (NP (NN IRF-7) (-LRB- -LRB-) (CD 35) (-RRB- -RRB-))))
                (CC and)
                (PP (IN for)
                  (NP
                    (NP (NN PU.1) (-LRB- -LRB-) (CD 36) (-RRB- -RRB-))
                    (, ,)
                    (NP
                      (NP (DT an) (VBG interacting) (NN partner))
                      (PP (IN of)
                        (NP (NN IRF-4))))))))))))
    (. .)))

(
  (S
    (S
      (S
        (S
          (VP (TO To)
            (VP (VB elucidate)
              (NP
                (NP (DT the) (NN relevance))
                (PP (IN of)
                  (NP (DT this) (NN mechanism)))
                (PP (IN for)
                  (NP
                    (NP (DT the) (NN regulation))
                    (PP (IN of)
                      (NP (NN IRF-4) (NN expression)))))))))
        (, ,)
        (NP (JJ various) (JJ leukemic) (NNS cells))
        (VP (VBD were)
          (VP (VBN treated)
            (PP (IN with)
              (NP (JJ demethylating) (NNS agents))))))
      (CC and)
      (S
        (NP (NNS promoters))
        (VP (VBD were)
          (VP (VBN sequenced)
            (PP (IN after)
              (NP (NN bisulfite) (NN treatment)))))))
    (. .)))

(
  (S
    (S
      (NP (PRP We))
      (VP (VBD found)
        (SBAR (IN that)
          (S
            (NP (NN IRF-4) (NN expression))
            (VP (MD could)
              (ADVP (RB indeed))
              (VP (VB be)
                (VP (VBN connected)
                  (PP (TO to)
                    (NP
                      (NP (DT the) (NN methylation) (NN status))
                      (PP (IN of)
                        (NP (JJ distinct) (NN CpG) (NNS motifs)))
                      (PP (IN in)
                        (NP (DT the) (NN IRF-4) (NN promoter))))))))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (NN Figure) (CD 4A)))
      (, ,)
      (NP (DT those) (NN CpG) (NNS sites))
      (VP (VBP are)
        (NP
          (NP
            (NP (VBN shown))
            (PRN (-LRB- -LRB-)
              (NP (NN bottom) (NN line))
              (-RRB- -RRB-)))
          (, ,)
          (SBAR
            (WHNP (WP$ whose) (NN hypermethylation))
            (S
              (VP (MD may)
                (VP (VB account)
                  (PP (IN for)
                    (NP
                      (NP (DT the) (NN absence))
                      (PP (IN of)
                        (NP
                          (NP (NN IRF-4) (NN expression))
                          (PP (IN in)
                            (NP (DT the) (JJ respective) (NNS cells))))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP
          (NP (CD One))
          (PP (IN of)
            (NP (PRP them))))
        (PRN (-LRB- -LRB-)
          (NP (NN #) (CD 54))
          (-RRB- -RRB-)))
      (VP (VBZ is)
        (ADJP (JJ adjacent)
          (PP (TO to)
            (NP (DT an) (VBN identified)
              (NP
                (NP (JJ regulatory) (NN element))
                (PRN (-LRB- -LRB-)
                  (NP (NN NFκB-site))
                  (-RRB- -RRB-))))))
        (, ,)
        (S
          (VP (VBG indicating)
            (NP
              (NP (DT a) (JJ possible) (NN involvement))
              (PP (IN of)
                (NP (DT this) (NN site))))))))
    (. .)))

(
  (S
    (S
      (PP (IN At)
        (NP
          (NP (CD two) (JJ further) (NN CpG) (NNS sites))
          (PRN (-LRB- -LRB-)
            (NP (NNP #) (CD 48) (, ,) (CD 45))
            (-RRB- -RRB-))))
      (NP
        (NP (DT the) (NN methylation) (NN status))
        (PP (IN in)
          (NP (NN IRF-4-positive))))
      (VP (VBD was)
        (ADJP
          (ADJP (JJR lower))
          (PP (IN than)
            (NP
              (NP (DT that))
              (PP (IN of)
                (NP (JJ IRF-4-negative) (NNS cells))))))))
    (. .)))

(
  (S
    (S
      (NP (DT These) (NN CpG) (NNS sites))
      (VP
        (VP (VBP are)
          (ADJP (JJ located)
            (PP (IN in)
              (NP
                (NP (DT an) (NN NFκB))
                (CC and)
                (NP
                  (NP (DT an) (NN SP1) (NN element))
                  (PRN (-LRB- -LRB-)
                    (NP (CD 31))
                    (-RRB- -RRB-)))))))
        (CC and)
        (VP
          (ADVP (RB thus))
          (VP (MD may)
            (ADVP (RB also))
            (VP (VB play)
              (NP (DT a) (NN role))
              (PP (IN in)
                (NP
                  (NP (NN regulation))
                  (PP (IN of)
                    (NP (NN IRF-4) (NN expression))))))))))
    (. .)))

(
  (S
    (S
      (NP (PRP It))
      (VP (VBZ has)
        (VP (VBN been)
          (VP (VBN shown)
            (SBAR (IN that)
              (S
                (NP (NN NFκB) (NNS elements))
                (VP (VBP play)
                  (NP (DT an) (JJ important) (NN role))
                  (PP (IN in)
                    (NP (NN IRF-4) (NN induction)))
                  (SBAR (IN as)
                    (S
                      (NP (NN IRF-4) (NN expression))
                      (VP (VBZ depends)
                        (PP (IN on)
                          (NP
                            (NP (NN binding))
                            (PP (IN of)
                              (NP (DT the) (NN transactivator) (NN c-Rel)))
                            (PP (TO to)
                              (NP
                                (NP (DT these) (NNS elements))
                                (PP (IN in)
                                  (NP (DT the)
                                    (NP
                                      (NP (NN IRF-4) (NN promoter))
                                      (PRN (-LRB- -LRB-)
                                        (NP (NN 31,37))
                                        (-RRB- -RRB-)))))))))))))))))))
    (. .)))

(
  (S
    (ADVP (RB Furthermore))
    (, ,)
    (NP
      (NP (NN methylation))
      (PP (IN of)
        (NP (DT the) (JJ central) (NN CpG)))
      (PP (IN in)
        (NP (DT the) (NN NFκB) (NN element))))
    (VP (VBZ inhibits)
      (NP
        (NP (NN binding))
        (PP (IN of)
          (NP
            (NP (DT the) (NN NFκB) (NN protein) (NNS complexes))
            (PRN (-LRB- -LRB-)
              (NP (CD 38))
              (-RRB- -RRB-)))))
      (, ,)
      (S
        (VP (VBG promoting)
          (NP
            (NP (DT the) (NN significance))
            (PP (IN of)
              (NP (DT the) (VBN observed) (NN methylation) (NNS differences)))
            (PP (IN in)
              (NP
                (ADJP
                  (ADJP (JJ IRF-4-positive))
                  (CC and)
                  (ADJP (JJ -negative)))
                (NNS cells)))))))
    (. .)))

(
  (S
    (S
      (PP (IN Via)
        (NP
          (ADJP (FW in) (FW vitro))
          (NN methylation)
          (CC and)
          (NN reporter) (NN gene) (NNS assays)))
      (NP (PRP we))
      (VP (MD could)
        (ADVP (RB clearly))
        (VP (NN appoint)
          (NP
            (NP (DT the) (NN silencing))
            (PP (IN of)
              (NP (DT the) (NN IRF-4) (NN promoter))))
          (PP (TO to)
            (NP
              (NP (DT a) (NN methylation) (NN effect))
              (, ,)
              (SBAR
                (WHNP (WDT which))
                (S
                  (VP (MD may)
                    (ADVP (RB thus))
                    (VP (VB be)
                      (NP
                        (NP (DT the) (NN mechanism))
                        (PP (IN of)
                          (NP (NN IRF-4) (NN deregulation))))
                      (ADVP (FW in) (FW vivo)))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (CD One) (JJ possible) (NN cause))
        (PP (IN for)
          (NP
            (NP (DT the) (JJ aberrant) (NN methylation))
            (PP (IN in)
              (NP (NN tumorigenesis))))))
      (VP (VBZ is)
        (NP
          (NP (DT an) (VBN increased) (NN level))
          (PP (IN of)
            (NP (NNS DNMTs))))
        (PP (IN during)
          (NP (DT the) (JJ pathogenetic) (NN process)))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP
          (NP (NN colon))
          (, ,)
          (NP (NN lung))
          (CC and)
          (NP (JJ hematologic) (NNS malignancies))))
      (, ,)
      (NP
        (NP (NN overexpression))
        (PP (IN of)
          (NP
            (NP (NN DNMT1))
            (, ,)
            (NP (DT a) (NN maintenance) (NN DNMT))
            (, ,))))
      (VP (VBZ has)
        (VP (VBN been)
          (VP (VBN detected)
            (PRN (-LRB- -LRB-)
              (NP (NN 39–41))
              (-RRB- -RRB-))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Furthermore))
      (, ,)
      (NP (PRP it))
      (VP (VBZ has)
        (VP (VBN been)
          (VP (VBN shown)
            (SBAR (IN that)
              (S
                (NP
                  (NP (NN CML) (NNS cells))
                  (PP (IN in)
                    (NP (DT the) (JJ acute) (NN phase))))
                (VP (VBD exhibited)
                  (NP
                    (NP (JJ elevated) (NNS levels))
                    (PP (IN of)
                      (NP (DT the) (CD three) (JJ known) (NNS DNMTs))))
                  (, ,)
                  (SBAR (IN while)
                    (S
                      (NP
                        (NP (NN CML) (NNS cells))
                        (PP (IN in)
                          (NP (JJ chronic) (NN phase))))
                      (VP (VBD expressed)
                        (NP
                          (NP (JJ normal) (NNS levels))
                          (PP (IN of)
                            (NP (NNS DNMTs))))
                        (SBAR (IN if)
                          (S
                            (VP (VBN compared)
                              (PP (IN with)
                                (NP
                                  (NP (JJ normal) (NN bone) (NN marrow) (NNS cells))
                                  (PRN (-LRB- -LRB-)
                                    (NP (CD 25))
                                    (-RRB- -RRB-)))))))))))))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Interestingly))
      (, ,)
      (NP
        (NP (DT a) (JJ positive) (NN correlation))
        (PP (IN between)
          (NP
            (NP (NN DNMT1) (NN expression) (NNS levels))
            (CC and)
            (NP
              (NP (NN hypermethylation))
              (PP (IN of)
                (NP (NN p15INK4b)))))))
      (VP (VBZ has)
        (VP (VBN been)
          (VP (VBN detected)
            (PP (IN in)
              (NP (NN AML) (-LRB- -LRB-) (CD 25) (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (DT this) (NN work)))
      (, ,)
      (NP (PRP we))
      (VP (VBD did) (RB not)
        (VP (VB detect)
          (NP
            (NP (JJ significant) (NN mRNA) (NN expression) (NNS differences))
            (PP (IN of)
              (NP (VBN selected)
                (NP (NN DNMT))
                (CC or)
                (NP (NN MBP))))))
        (, ,)
        (S
          (VP (VBG making)
            (NP
              (NP (PRP it))
              (NP
                (NP (DT an) (JJ unlikely) (NN cause))
                (PP (IN for)
                  (NP
                    (NP (DT the) (VBN observed)
                      (NP
                        (NP (NN methylation))
                        (CC and)
                        (ADVP (RB thus))
                        (NP (NN IRF-4) (NN expression)))
                      (NNS differences))
                    (PP (IN in)
                      (NP (NN leukemia) (NNS cells)))))))))))
    (. .)))

(
  (S
    (S
      (NP (DT The) (NN finding)
        (SBAR (IN that)
          (S
            (NP (NN IRF-4) (NN expression))
            (VP (VBZ is)
              (VP (VBN silenced)
                (PP (IN by)
                  (NP (NN promoter) (NN hypermethylation))))))))
      (VP (MD might)
        (VP (VB represent)
          (NP
            (NP (DT a) (NN mechanism))
            (SBAR
              (WHNP (WDT that))
              (S
                (VP (VBZ accounts)
                  (PP (IN for)
                    (NP
                      (NP (DT the)
                        (ADJP (RB previously) (VBN observed))
                        (NN loss))
                      (PP (IN of)
                        (NP
                          (NP (NN IRF-4) (NN expression))
                          (PP (IN in)
                            (NP (NN CML))))))))))))))
    (. .)))

(
  (S
    (ADVP (RB Indeed))
    (, ,)
    (NP
      (NP (JJ several) (JJ clinical) (NNS trials))
      (PP (IN with)
        (NP
          (NP (NN leukemia) (NNS patients))
          (CC and)
          (NP
            (NP (NNS patients))
            (PP (IN with)
              (NP (JJ myelodysplastic) (NNS syndromes)))))))
    (VP (VBD demonstrated)
      (NP
        (NP (DT the) (JJ potential) (JJ clinical) (NN benefit))
        (PP (IN of)
          (NP
            (NP (DT a) (NN treatment))
            (PP (IN with)
              (NP
                (NP (JJ demethylating) (NNS agents))
                (PRN (-LRB- -LRB-)
                  (NP (NN 42–45))
                  (-RRB- -RRB-))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP
          (NP (DT The) (NN expression))
          (PP (IN of)
            (NP (DT another) (NN IRF))))
        (, ,)
        (NP
          (NP (NN IFN) (NN consensus) (NN sequence) (NN binding) (NN protein))
          (PRN (-LRB- -LRB-)
            (NP (NN ICSBP/IRF-8))
            (-RRB- -RRB-)))
        (, ,))
      (VP (VBZ is)
        (VP (VBN impaired)
          (PP (IN in)
            (NP
              (NP (JJ myeloid) (NNS leukemias))
              (NP
                (ADVP (RB especially))
                (NP
                  (NP (NN CML))
                  (PRN (-LRB- -LRB-)
                    (NP (NN 27,46,47))
                    (-RRB- -RRB-)))))))))
    (. .)))

(
  (S
    (S (CC But)
      (PP (IN in) (NN contrast) (TO to)
        (NP (NN IRF-4)))
      (, ,)
      (S
        (NP
          (NP (DT the) (NN loss))
          (PP (IN of)
            (NP (DT this) (NN IRF))))
        (VP (MD could) (RB not)
          (VP (VB be)
            (VP (VBD reverted)
              (PP (IN in)
                (NP
                  (NP (JJ ICSBP-negative) (NN cell) (NNS lines))
                  (PRN (-LRB- -LRB-)
                    (NP (NN EM-2) (, ,) (NN CML-T1) (, ,) (NN K-562)
                      (CC and)
                      (CD LAMA-84))
                    (-RRB- -RRB-))))
              (PP (IN by)
                (NP
                  (NP (NN treatment))
                  (PP (IN with)
                    (NP
                      (NP (NN AzadC))
                      (PRN (-LRB- -LRB-)
                        (NP (NN Figure) (CD 6))
                        (-RRB- -RRB-))))))))))
      (CC and)
      (S
        (NP (NN AzadC))
        (VP (VBZ has)
          (NP (DT no) (NN effect))
          (PP (IN on)
            (NP
              (NP (NN ICSBP) (NNS levels))
              (PP (IN in)
                (NP
                  (NP (JJ ICSBP-positive) (NN U-937) (NNS cells))
                  (PRN (-LRB- -LRB-)
                    (NP (NN Figure) (CD 6))
                    (-RRB- -RRB-)))))))))
    (. .)))

(
  (S
    (S
      (NP (DT These) (NNS data))
      (VP (VBP suggest)
        (NP
          (NP (DT a) (JJ distinct) (JJ regulatory) (NN mechanism))
          (PP (IN for)
            (NP (DT these) (CD two) (NNS IRFs))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN IRF-4))
        (, ,)
        (ADJP (JJ similar)
          (PP (TO to)
            (NP (JJ many) (JJ other) (JJ classical) (NN tumor) (NN suppressor) (NNS genes)
              (NP
                (NP (NN p15INK4b))
                (, ,)
                (NP (NN p16INK4a))
                (CC or)
                (NP (NN p53))))))
        (, ,))
      (VP (MD may)
        (ADVP (RB thus))
        (VP (VB be)
          (NP
            (NP (DT a) (NN subject))
            (PP (IN of)
              (NP
                (NP (NNS alterations))
                (PP (IN in)
                  (NP
                    (NP (DT the) (NN promoter) (NN methylation) (NN status))
                    (VP (VBG leading)
                      (PP (TO to)
                        (NP
                          (NP (NN expression) (NNS changes))
                          (, ,)
                          (SBAR
                            (WHNP (WDT which))
                            (S
                              (VP (MD might)
                                (VP (VB contribute)
                                  (PP (TO to)
                                    (NP
                                      (NP (DT the)
                                        (NP (NN initiation))
                                        (CC and/or)
                                        (NP (NN progression)))
                                      (PP (IN of)
                                        (NP (NN cancer))))))))))))))))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Still))
      (, ,)
      (NP
        (NP (DT the) (JJ obvious) (JJ functional) (NN diversity))
        (PP (IN of)
          (NP (NN IRF-4))))
      (VP
        (VP (VBZ remains)
          (ADJP (JJ remarkable)))
        (CC and)
        (VP (MD cannot)
          (VP (VB be)
            (ADVP (RB fully))
            (VP (VBN explained)
              (PP (IN by)
                (NP (DT the) (NN IRF-4) (NN promoter) (NN methylation) (NN status))))))))
    (. .)))

(
  (S
    (S
      (PP (IN For)
        (NP (NN example)))
      (, ,)
      (NP (NN IRF-4))
      (VP (VBZ is)
        (ADVP (RB primarily))
        (VP (VBN known)
          (PP (IN for)
            (NP (PRP$ its) (JJ oncogenic) (NNS features))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP
          (NP (JJ multiple) (NN myeloma))
          (PRN (-LRB- -LRB-)
            (NP (NN MM))
            (-RRB- -RRB-))))
      (NP
        (NP (DT a) (NN translocation))
        (PP (IN on)
          (NP (NN chromosome) (CD 14q))))
      (VP (VBD was)
        (VP (VBN reported)
          (S
            (VP (TO to)
              (VP (VB lead)
                (PP (TO to)
                  (NP
                    (NP (DT a) (NN fusion) (NN gene))
                    (PP (IN of)
                      (NP
                        (NP
                          (NP
                            (NP (NN immunoglobulin) (NN heavy-chain))
                            (PRN (-LRB- -LRB-)
                              (NP (NN IgH))
                              (-RRB- -RRB-)))
                          (CC and)
                          (NP (NN IRF-4)))
                        (VP (VBG resulting)
                          (PP (IN in)
                            (NP
                              (NP (DT a) (JJ subsequent) (NN overexpression))
                              (PP (IN of)
                                (NP
                                  (NP (NN IRF-4))
                                  (PRN (-LRB- -LRB-)
                                    (NP (NN 48,49))
                                    (-RRB- -RRB-)))))))))))))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (NN addition)))
      (, ,)
      (NP (JJ abundant) (NN IRF-4) (NN expression))
      (VP (VBD was)
        (VP (VBN found)
          (S
            (VP (TO to)
              (VP (VB be)
                (NP
                  (NP (DT a) (NN marker))
                  (PP (IN for)
                    (NP
                      (NP (JJ various) (NNS subsets))
                      (PP (IN of)
                        (NP
                          (NP (NNS lymphomas))
                          (, ,)
                          (CONJP (JJ such) (IN as))
                          (NP (JJ diffuse) (JJ large) (NN B-cell) (NNS lymphomas))
                          (, ,)
                          (NP
                            (NP (JJ primary) (NN effusion) (NN lymphoma))
                            (, ,)
                            (CC and)
                            (NP (JJ marginal) (NN zone) (NN lymphoma)))
                          (, ,)
                          (CC and)
                          (NP
                            (NP (JJ adult) (NN T-cell) (NN leukemia))
                            (PRN (-LRB- -LRB-)
                              (NP (NN 11,31,50–52))
                              (-RRB- -RRB-))))))))))))))
    (. .)))

(
  (S
    (S
      (NP (DT This))
      (VP (VBZ draws)
        (NP
          (NP (DT a)
            (ADJP (RBR more) (JJ complex))
            (NN picture))
          (PP (IN of)
            (NP
              (NP (DT the) (NN role))
              (PP (IN of)
                (NP (NN IRF-4))))))))
    (. .)))

(
  (S
    (NP
      (NP (NN Down-regulation))
      (PP (IN of)
        (NP (NN IRF-4))))
    (VP (MD may)
      (VP (VB promote)
        (NP (NN leukemogenesis))
        (PP (IN in)
          (NP
            (NP
              (NP (JJ myeloid) (NN cell) (NN context))
              (PRN (-LRB- -LRB-)
                (NP (CD 3))
                (-RRB- -RRB-)))
            (, ,)
            (SBAR
              (WHNP (WDT which))
              (S
                (VP (VBD was)
                  (ADVP (RB recently))
                  (VP (VBN confirmed)
                    (PP (IN in)
                      (NP
                        (NP (JJ IRF-4−/−) (NN ICSBP−/−) (JJ double) (JJ knock-out) (NNS mice))
                        (PRN (-LRB- -LRB-)
                          (NP (CD 53))
                          (-RRB- -RRB-)))))
                  (, ,)
                  (SBAR (IN while)
                    (S
                      (NP (NN IRF-4) (NN up-regulation))
                      (VP (MD may)
                        (VP (VB induce)
                          (NP (DT a) (NN growth) (NN advantage))
                          (PP (IN in)
                            (NP
                              (NP (NNS lymphomas))
                              (CC or)
                              (NP (NN MM) (-LRB- -LRB-) (CD 48) (-RRB- -RRB-)))))))))))))))
    (. .)))

(
  (S
    (S
      (S
        (VP (VBN Taken)
          (ADVP (RB together))))
      (, ,)
      (NP (PRP$ our) (NNS data))
      (VP (VBP suggest)
        (SBAR
          (SBAR (IN that)
            (S
              (NP (NN IRF-4) (NN promoter) (NN methylation))
              (VP (VBZ regulates)
                (NP (NN IRF-4) (NN expression)))))
          (, ,)
          (CC and)
          (SBAR (IN that)
            (S
              (NP
                (NP (JJ aberrant) (NN expression))
                (PP (IN of)
                  (NP (NN IRF-4)))
                (PP (IN in)
                  (NP
                    (NP (JJ certain) (NNS types))
                    (PP (IN of)
                      (NP (NN leukemia))))))
              (VP (MD may)
                (VP (VB be)
                  (NP
                    (NP (DT a) (NN consequence))
                    (PP (IN of)
                      (NP (NN IRF-4) (NN promoter) (NN hypermethylation)))))))))))
    (. .)))

(
  (S
    (NP
      (NP (NN Figure))
      (CC and)
      (NP (NN Table))
      (NP (NNS captions)))))

(
  (S
    (NP
      (NP (NN Figure) (CD 1))
      (: :)
      (NP
        (NP
          (NP (NN Correlation))
          (PP (IN of)
            (NP (NN IRF-4) (NN mRNA) (NN expression))))
        (CC and)
        (NP
          (NP (JJ nucleotide) (NNS changes))
          (PP (IN in)
            (NP (DT the) (NN IRF-4) (NN promoter)))))
      (. .))))

(
  (S
    (S
      (NP
        (NP
          (LST (-LRB- -LRB-) (LS A) (-RRB- -RRB-))
          (NN RT–PCR))
        (PP (IN of)
          (NP (JJ different) (JJ hematopoietic) (NN cell) (NNS lines)))))
    (. .)))

(
  (S
    (NP
      (LST (-LRB- -LRB-) (LS B) (-RRB- -RRB-))
      (NP (NN nucleotide) (NNS changes))
      (PP (IN in)
        (NP
          (NP (DT the) (NN promoter))
          (PP (IN of)
            (NP
              (NP
                (ADJP
                  (ADJP (JJ IRF-4-positive))
                  (CC or)
                  (ADJP (JJ -negative)))
                (NNS cells))
              (PP (IN in)
                (NP
                  (NP (NN comparison))
                  (PP (TO to)
                    (NP
                      (NP
                        (NP (DT the) (NN germline) (NN sequence))
                        (PP (IN at)
                          (NP (NNS positions)
                            (QP (CD 98) (, ,) (CD 111)
                              (CC and)
                              (CD 1063)))))
                      (-LRB- -LRB-)
                      (NP (NN GenBank) (NN accession) (NN no))))))))))
      (. .))))

(
  (S
    (S
      (LST (CD U52683) (-RRB- -RRB-))
      (, ,)
      (S
        (VP (VBG representing)
          (NP
            (NP (NN nucleotide) (NN −1081))
            (, ,)
            (NP
              (NP
                (NP
                  (NP (CD −1068))
                  (CC and)
                  (NP (CD −116)))
                (PRN (-LRB- -LRB-)
                  (NP (CD 30))
                  (-RRB- -RRB-)))
              (CC or)
              (NP
                (NP
                  (NP (CD −1094))
                  (, ,)
                  (NP (CD −1081))
                  (CC and)
                  (NP (CD −129)))
                (PRN (-LRB- -LRB-)
                  (NP (CD 31))
                  (-RRB- -RRB-)))))
          (, ,)
          (ADVP (RB respectively)))))
    (. .)))

(
  (S
    (NP
      (NP (NN Figure) (CD 2))
      (: :)
      (NP
        (NP (NN Expression))
        (PP (IN of)
          (NP (NN IRF-4)))
        (PP (IN in)
          (NP
            (NP (JJ hematopoietic) (NNS cells))
            (PP (IN after)
              (NP
                (NP (NN treatment))
                (PP (IN with)
                  (NP (NN AzadC))))))))
      (. .))))

(
  (S
    (S
      (NP
        (NP (JJ Representative) (NNS cells))
        (CC and)
        (NP (NNS experiments)))
      (VP (VBP are)
        (VP (VBN shown))))
    (. .)))

(
  (S
    (NP
      (NP
        (LST (-LRB- -LRB-) (LS A) (-RRB- -RRB-))
        (NN RT–PCR))
      (PP (IN after)
        (NP
          (NP (NN incubation))
          (PP (IN of)
            (NP
              (NP (NN CML-T1))
              (CC and)
              (NP (NN EM-2))))
          (PP (IN with)
            (NP
              (NP
                (NP
                  (NP (CD 0.5) (, ,) (CD 1)
                    (CC and)
                    (CD 3) (NN µM) (NN AzadC))
                  (PP (IN for)
                    (NP (CD 72) (NN h))))
                (: ;)
                (NP
                  (NP
                    (LST (-LRB- -LRB-) (LS B) (-RRB- -RRB-))
                    (NN RT–PCR))
                  (PP (IN after)
                    (NP
                      (NP (NN treatment))
                      (PP (IN of)
                        (NP
                          (NP (NN CML-T1))
                          (CC and)
                          (NP (NN EM-2))))
                      (PP (IN with)
                        (NP
                          (NP (CD 3) (NN µM) (NN AzadC))
                          (PP (IN for)
                            (NP
                              (QP (CD 24) (, ,) (CD 48)
                                (CC and)
                                (CD 72))
                              (NN h))))))))
                (: ;))
              (-LRB- -LRB-) (NN C) (-RRB- -RRB-) (NN immunoblotting)))))
      (PP (IN after)
        (NP
          (NP (NN treatment))
          (PP (IN of)
            (NP
              (NP (NN CML-T1))
              (CC and)
              (NP
                (NP
                  (NP
                    (NP
                      (NP
                        (NP (CD LAMA-84))
                        (PP (IN with)
                          (NP
                            (QP (CD 1)
                              (CC and)
                              (CD 3))
                            (NN µM) (NN AzadC))))
                      (PP (IN for)
                        (NP (CD 72) (NN h))))
                    (: ;)
                    (NP
                      (NP
                        (LST (-LRB- -LRB-) (LS D) (-RRB- -RRB-))
                        (NN RT–PCR))
                      (PP (IN after)
                        (NP
                          (NP (NN treatment))
                          (PP (IN of)
                            (NP (NN BV-173)))
                          (PP (IN for)
                            (NP
                              (QP (CD 24) (, ,) (CD 48)
                                (CC and)
                                (CD 72))
                              (NN h)))))))
                  (CC and)
                  (NP (CD RPMI-8226)))
                (PP (IN for)
                  (NP (CD 72) (NN h))))))
          (PP (IN with)
            (NP (CD 3) (NN µM) (NN AzadC)))))
      (. .))))

(
  (S
    (NP
      (NP (NN Figure) (CD 3))
      (: :)
      (NP
        (NP (NN Restriction-PCR-assay))
        (PP (IN of)
          (NP (DT the) (NN IRF-4) (NN promoter)))
        (PP (IN in)
          (NP (JJ hematopoietic) (NNS cells))))
      (. .))))

(
  (S
    (S
      (LST (-LRB- -LRB-) (LS A) (-RRB- -RRB-))
      (VP (VBN Simplified)
        (NP
          (NP (NN structure))
          (PP (IN of)
            (NP (DT the) (NN CpG) (NNS sites))))
        (PP (IN in)
          (NP
            (NP (DT the) (JJ human) (NN IRF-4) (NN promoter) (NN region))
            (VP (VBG including)
              (NP (NN exon) (CD 1)))))))
    (. .)))

(
  (S
    (S
      (NP (DT Each) (NN CpG) (NN motif))
      (VP (VBZ is)
        (VP (VBN shown)
          (PP (IN as)
            (NP
              (NP (NN circle))
              (CC and)
              (NP
                (NP (JJ numbered))
                (PRN (-LRB- -LRB-)
                  (NP
                    (NP (JJ above))
                    (, ,)
                    (NP
                      (NP (NN labeling))
                      (VP (VBG beginning)
                        (PP (IN from)
                          (NP
                            (NP (DT the) (JJ 3′) (NN end))
                            (VP (VBG moving)
                              (ADVP (RB upstream))))))))
                  (-RRB- -RRB-))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP
          (NP (NN Restriction) (NNS sites))
          (, ,)
          (NP
            (NP
              (NP (NNS fragments))
              (PRN (-LRB- -LRB-)
                (NP (NNP F1) (, ,) (NNP F2))
                (-RRB- -RRB-)))
            (PP (IN of)
              (NP (DT the) (NN restriction-PCR-assay))))
          (CC and)
          (NP (NNS regions)))
        (VP (VBN amplified)
          (PP (IN after)
            (NP (NN bisulfite) (NN treatment)))
          (PP (IN for)
            (NP (NN sequencing)))))
      (VP (VBP are)
        (VP (VBN shown)
          (ADVP (IN below)))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NNS numbers))
        (PP (IN in)
          (NP (NNS italics))))
      (VP (VBP refer)
        (PP (TO to)
          (NP
            (NP (DT the) (NN sequence) (NN data))
            (PP (IN by)
              (NP
                (NP
                  (NP (NNP Grossman) (FW et) (FW al))
                  (. .))
                (PRN (-LRB- -LRB-)
                  (NP (CD 30))
                  (-RRB- -RRB-))))))))
    (. .)))

(
  (S
    (S
      (NP (-LRB- -LRB-)
        (NP
          (NP (NN B))
          (CC and)
          (NP (NN C)))
        (-RRB- -RRB-))
      (NP (NN Restriction-PCR-assay)))
    (. .)))

(
  (S
    (NP
      (NP (NN Restriction))
      (PP (IN of)
        (NP (NN DNA)))
      (PP (IN with)
        (NP
          (NP
            (NP (NN EcoRI))
            (PRN (-LRB- -LRB-)
              (NP
                (NP (NN E))
                (, ,)
                (NP (DT no) (NN recognition) (NN site)))
              (-RRB- -RRB-)))
          (, ,)
          (NP
            (NP (NN HpaII))
            (PRN (-LRB- -LRB-)
              (FRAG
                (NP (NN H))
                (, ,) (JJ sensitive))
              (-RRB- -RRB-)))
          (, ,)
          (NP
            (NP (NN Bsp143II))
            (PRN (-LRB- -LRB-)
              (FRAG
                (NP (NN BII))
                (, ,) (JJ sensitive))
              (-RRB- -RRB-)))
          (, ,)
          (NP
            (NP
              (NP
                (NP (NN Bsh1236I))
                (PRN (-LRB- -LRB-)
                  (FRAG
                    (NP (NN BI))
                    (, ,) (JJ sensitive))
                  (-RRB- -RRB-)))
              (CC and)
              (NP (NN MspI)))
            (PRN (-LRB- -LRB-)
              (NP (NN M))
              (, ,)
              (NP (JJ resistant))
              (-RRB- -RRB-)))
          (CC and)
          (NP (JJ subsequent) (NN PCR) (NN amplification))))
      (. .))))

(
  (S
    (S
      (NP
        (NP (CD Three) (JJ representative)
          (NP (JJ IRF-4-negative)
            (PRN (-LRB- -LRB-)
              (NP
                (NP (NN K-562))
                (, ,)
                (NP (NN CML-T1))
                (, ,)
                (NP (NN EM-2)))
              (-RRB- -RRB-))
            (CC and)
            (CD two) (JJ IRF-4-positive) (NN cell) (NNS lines)))
        (PRN (-LRB- -LRB-)
          (NP
            (NP (NN SD-1))
            (, ,)
            (NP (NN BV-173)))
          (-RRB- -RRB-)))
      (VP (VBP are)
        (VP (VBN shown))))
    (. .)))

(
  (S
    (S
      (NP (NN IRF-4) (NN expression))
      (VP (VBZ is)
        (VP (VBN denoted)
          (PP (IN on)
            (NP (DT the) (JJ right))))))
    (. .)))

(
  (S
    (S
      (S
        (LST (-LRB- -LRB-) (LS B) (-RRB- -RRB-))
        (VP (JJ PCR-fragment)
          (NP (CD 1)
            (PRN (-LRB- -LRB-)
              (NP (NN F1))
              (-RRB- -RRB-)))))
      (: ;)
      (S
        (LST (-LRB- -LRB-) (LS C) (-RRB- -RRB-))
        (VP (JJ PCR-fragment)
          (NP
            (NP (CD 2))
            (PRN (-LRB- -LRB-)
              (NP (NN F2))
              (-RRB- -RRB-))))))
    (. .)))

(
  (S
    (S
      (NP (NN Figure) (CD 4))
      (: :)
      (NP
        (NP (NN Methylation) (NN pattern))
        (PP (IN of)
          (NP (NN CpG) (NNS sites)))
        (PP (IN in)
          (NP (DT the) (NN IRF-4) (NN promoter) (NN region)))))
    (. .)))

(
  (S
    (S
      (NP (NN Methylation))
      (VP (VBZ is)
        (VP (VBN detected)
          (PP (IN via)
            (NP
              (NP (NN sequencing))
              (PP (IN of)
                (NP
                  (NP (JJ bisulfite-treated) (NN DNA))
                  (PP (IN from)
                    (NP (JJ hematopoietic) (NNS cells))))))))))
    (. .)))

(
  (S
    (NP
      (NP
        (LST (-LRB- -LRB-) (LS A) (-RRB- -RRB-))
        (JJ Schematic) (NN figure))
      (PP (IN of)
        (NP
          (NP (DT the) (NN IRF-4) (NN promoter) (NN region))
          (PRN (-LRB- -LRB-)
            (VP (VB see)
              (NP (NN Figure) (NN 3A)))
            (-RRB- -RRB-))))
      (PP (IN for)
        (NP (DT each) (NN cell) (NN line)))
      (. .))))

(
  (S
    (S
      (NP (DT Each) (NN CpG) (NN motif))
      (VP (VBZ is)
        (VP (VBN shown)
          (PP (IN as)
            (NP
              (NP
                (ADJP
                  (ADJP
                    (ADJP
                      (ADJP (JJ circle))
                      (CC and)
                      (ADJP (JJ numbered)))
                    (PRN (-LRB- -LRB-)
                      (FRAG
                        (ADVP (RB above))
                        (, ,)
                        (NP
                          (NP (NN labeling))
                          (VP (VBG beginning)
                            (PP (IN from)
                              (NP
                                (NP (DT the) (JJ 3′) (NN end))
                                (VP (VBG moving)
                                  (ADVP (RB upstream))))))))
                      (-RRB- -RRB-)))
                  (, ,)
                  (ADJP (JJ white)))
                (NNS circles))
              (VP (JJ mean)
                (NP
                  (NP
                    (NP (DT no) (VBN methylated) (NN clone))
                    (PRN (-LRB- -LRB-)
                      (QP (IN from) (CD eight))
                      (-RRB- -RRB-)))
                  (, ,)
                  (NP (NN gray) (NNS circles))
                  (NP (JJ mean)
                    (NP
                      (QP (CD one) (TO to) (CD four))
                      (VBN methylated) (NNS clones))
                    (CC and)
                    (NP (JJ black) (NNS circles))
                    (NP (NN mean)
                      (QP (CD five) (TO to) (CD eight))
                      (VBN methylated) (NNS clones))))))))))
    (. .)))

(
  (S
    (S
      (NP (NN IRF-4) (NN expression))
      (VP (VBZ is)
        (VP (VBN denoted)
          (PP (IN on)
            (NP (DT the) (JJ right))))))
    (. .)))

(
  (S
    (PP (IN Below))
    (, ,)
    (NP (NN CpG) (NNS sites))
    (VP (NN maybe)
      (NP
        (ADJP (JJ responsible)
          (PP (IN for)
            (NP
              (NP
                (NP (JJ methylation-dependent) (NN IRF-4) (NN silencing))
                (PRN (-LRB- -LRB-)
                  (NP (NN arrows))
                  (-RRB- -RRB-)))
              (: ;)
              (NP
                (NP (NN R1))
                (, ,)
                (NP
                  (NP (NN region))
                  (PP (IN with)
                    (NP
                      (ADJP (RB generally) (JJ high))
                      (NN methylation))))
                (: ;)
                (NP (NN R2))
                (, ,)
                (NP
                  (NP (NN region))
                  (PP (IN with)
                    (NP
                      (NP (NN correlation))
                      (PP (IN between)
                        (NP
                          (NP (NN methylation))
                          (CC and)
                          (NP (NN IRF-4) (NN expression)))))))
                (: ;)
                (NP (NN R3))))))
        (, ,) (NN region))
      (PP (IN with)
        (NP
          (ADJP (RB generally) (JJ low))
          (NN methylation))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (JJ Putative) (VBG binding) (NNS sites))
        (PP (IN for)
          (NP (NN transcription) (NNS factors))))
      (VP (VBP are)
        (VP (VBN shown)
          (ADVP (RB above))
          (PRN (-LRB- -LRB-)
            (FRAG
              (NP (CD 5×) (NN AP1))
              (, ,)
              (NP (CD 3×) (NN Sp1))
              (, ,)
              (NP (CD 2×) (NN Ets-1))
              (, ,)
              (NP (CD 2×) (NN κB))
              (, ,)
              (NP (CD 1×) (NN NF-3))
              (, ,)
              (NP (CD 1×) (NN CD28RE))
              (, ,)
              (NP (CD 1×) (NN PU.1)))
            (-RRB- -RRB-)))))
    (. .)))

(
  (S
    (NP
      (NP
        (NP
          (LST (-LRB- -LRB-) (LS B) (-RRB- -RRB-))
          (NP (JJ Schematic) (NN figure))
          (PP (IN of)
            (NP (JJ specific) (NN region) (CD 2))))
        (PRN (-LRB- -LRB-)
          (NP (NN R2))
          (-RRB- -RRB-)))
      (: :)
      (S
        (NP
          (NP (NN CpG) (NNS sites))
          (PP (IN from)
            (NP
              (NP (NNP #) (CD 10))
              (TO to)
              (NP (NNP #) (CD 22)))))
        (VP (VBP are)
          (VP (VBN shown)
            (ADVP (RB above)))))
      (. .))))

(
  (S
    (S
      (NP
        (NP
          (NP (NN Number))
          (PP (IN of)
            (NP (VBN methylated) (NNS clones))))
        (PRN (-LRB- -LRB-)
          (PP (IN from)
            (NP (CD eight)))
          (-RRB- -RRB-)))
      (VP (VBZ is)
        (VP (VBN shown)
          (PP (IN for)
            (NP (DT each) (NN cell) (NN line))))))
    (. .)))

(
  (S
    (NP
      (NP (NN Figure) (CD 5))
      (: :)
      (NP
        (NP (NN Investigation))
        (PP (IN of)
          (NP
            (NP (JJ putative) (NNS mechanisms))
            (PP (IN for)
              (NP (NN IRF-4) (NN deregulation))))))
      (. .))))

(
  (S
    (NP
      (NP (-LRB- -LRB-) (NN A–C) (-RRB- -RRB-) (NN Influence))
      (PP (IN of)
        (NP
          (ADJP (FW in) (FW vitro))
          (NN methylation)))
      (PP (IN on)
        (NP
          (NP (DT the) (NN activity))
          (PP (IN of)
            (NP (DT an) (NN IRF-4) (NN promoter-reporter) (NN gene) (NN construct)))))
      (. .))))

(
  (S
    (NP
      (NP
        (LST (-LRB- -LRB-) (LS A) (-RRB- -RRB-))
        (NN Control))
      (PP (IN of)
        (NP (JJ complete) (NN methylation)))
      (PP (IN via)
        (NP (NN restriction)))
      (. .))))

(
  (S
    (NP
      (NP (NN Digestion))
      (PP (IN of)
        (NP (DT the) (NN construct)))
      (PP
        (PP (IN before)
          (S
            (PRN (-LRB- -LRB-)
              (NP (NNS lanes)
                (QP (CD 2) (, ,) (CD 4)
                  (CC and)
                  (CD 6)))
              (-RRB- -RRB-))))
        (CC and)
        (PP (IN after)
          (NP
            (NP (NN methylation))
            (PRN (-LRB- -LRB-)
              (NP (NNS lanes)
                (QP (CD 1) (, ,) (CD 3)
                  (CC and)
                  (CD 5)))
              (-RRB- -RRB-)))))
      (PP (IN with)
        (NP
          (NP (JJ respective)
            (ADJP
              (ADJP (JJ methylation-sensitive)
                (PRN (-LRB- -LRB-)
                  (NP
                    (NP (NN HpaII))
                    (, ,)
                    (NP (NNS lanes)
                      (QP (CD 1)
                        (CC and)
                        (CD 2))))
                  (-RRB- -RRB-)))
              (CC and)
              (ADJP (JJ -resistant)))
            (NNS endonucleases))
          (PRN (-LRB- -LRB-)
            (NP
              (NP (NN MspI))
              (, ,)
              (NP (NNS lanes)
                (QP (CD 3)
                  (CC and)
                  (CD 4))))
            (-RRB- -RRB-))))
      (. .))))

(
  (S
    (NP
      (NP (-LRB- -LRB-)
        (NP
          (NP (NN B))
          (CC and)
          (NP (NN C)))
        (-RRB- -RRB-) (NN Reporter) (NN gene) (NNS assays))
      (PP (IN with)
        (NP
          (NP
            (NP (JJ non-methylated) (NN control))
            (PRN (-LRB- -LRB-)
              (NP (NN co))
              (-RRB- -RRB-)))
          (CC and)
          (NP
            (ADJP
              (ADJP
                (ADVP (FW in) (FW vitro))
                (VBN methylated))
              (PRN (-LRB- -LRB-)
                (NP (NN met))
                (-RRB- -RRB-)))
            (NN IRF-4) (NN promoter) (NNS constructs))
          (CC and)
          (NP
            (NP (NN SD-1))
            (PRN (-LRB- -LRB-)
              (NP (NN B))
              (-RRB- -RRB-)))
          (CC or)
          (NP
            (NP (NN Jurkat) (NNS cells))
            (PRN (-LRB- -LRB-)
              (NP (NN C))
              (-RRB- -RRB-)))))
      (. .))))

(
  (S
    (S
      (NP (DT The) (NN promoter) (NN activity))
      (VP (VBZ is)
        (VP (VBN displayed)
          (PP (IN as)
            (NP
              (NP (JJ fold) (NN increase))
              (PP (TO to)
                (NP
                  (NP (JJ non-methylated) (NN construct))
                  (PRN (-LRB- -LRB-)
                    (PP (IN via)
                      (NP
                        (NP (NN ratio))
                        (PP (IN of)
                          (NP (NN firefly) (TO to) (NN renilla) (NN luciferase)))))
                    (-RRB- -RRB-)))))))))
    (. .)))

(
  (S
    (S
      (LST (-LRB- -LRB-) (LS D) (-RRB- -RRB-))
      (NP
        (NP (NN Expression))
        (PP (IN of)
          (NP
            (NP (NN DNMT))
            (CC and)
            (NP (NN MBP) (NN mRNA))))
        (PP (IN in)
          (NP (JJ various) (JJ hematopoietic) (NNS cells)))))
    (. .)))

(
  (S
    (NP
      (NP
        (NP (NN RT–PCR))
        (PP (IN of)
          (NP (JJ various) (JJ hematopoietic) (NNS cells))))
      (: :)
      (NP
        (NP
          (NP (CD SD-1))
          (PRN (-LRB- -LRB-)
            (NP (NNP lane) (CD 1))
            (-RRB- -RRB-)))
        (, ,)
        (NP
          (NP (CD RPMI-8226))
          (PRN (-LRB- -LRB-)
            (NP (NNP lane) (CD 2))
            (-RRB- -RRB-)))
        (, ,)
        (NP
          (NP
            (NP (CD BV-173))
            (PRN (-LRB- -LRB-)
              (NP (NNP lane) (CD 3))
              (-RRB- -RRB-)))
          (, ,)
          (NP
            (NP
              (NP (NN U-937))
              (PRN (-LRB- -LRB-)
                (NP (NNP lane) (CD 4))
                (-RRB- -RRB-)))
            (, ,)
            (NP
              (NP (NN CML-T1))
              (PRN (-LRB- -LRB-)
                (NP (NNP lane) (CD 5))
                (-RRB- -RRB-)))
            (, ,)
            (NP
              (NP (NN LAMA-84))
              (PRN (-LRB- -LRB-)
                (NP (NNP lane) (CD 6))
                (-RRB- -RRB-)))
            (, ,)
            (NP
              (NP (NN Jurkat))
              (PRN (-LRB- -LRB-)
                (NP (NNP lane) (CD 7))
                (-RRB- -RRB-)))
            (, ,)
            (NP
              (NP (NN EM-2))
              (PRN (-LRB- -LRB-)
                (NP (NNP lane) (CD 8))
                (-RRB- -RRB-)))
            (CC and)
            (NP
              (NP (NN K-562))
              (PRN (-LRB- -LRB-)
                (NP (NNP lane) (CD 9))
                (-RRB- -RRB-))))))
      (. .))))

(
  (S
    (S
      (NP (NN β-Actin))
      (VP (VBZ is)
        (VP (VBN used)
          (PP (IN as)
            (NP (NN reference))))))
    (. .)))

(
  (S
    (NP
      (NP (NN Figure) (CD 6))
      (: :)
      (NP
        (NP (NN Expression))
        (PP (IN of)
          (NP (NN ICSBP)))
        (PP (IN in)
          (NP
            (NP (JJ hematopoietic) (NNS cells))
            (PP (IN after)
              (NP
                (NP (NN treatment))
                (PP (IN with)
                  (NP (NN AzadC))))))))
      (. .))))

(
  (S
    (S
      (NP (JJ Representative) (NNS experiments))
      (VP (VBP are)
        (VP (VBN shown))))
    (. .)))

(
  (S
    (NP
      (NP
        (LST (-LRB- -LRB-) (LS A) (-RRB- -RRB-))
        (NP (NN RT–PCR))
        (PP (IN after)
          (NP
            (NP (NN treatment))
            (PP (IN of)
              (NP
                (NP (NN CML-T1))
                (CC and)
                (NP (NN EM-2))))
            (PP (IN with)
              (NP
                (NP (CD 3) (JJ µM) (NN AzadC))
                (PP (IN for)
                  (NP
                    (QP (CD 24) (, ,) (CD 48)
                      (CC and)
                      (CD 72))
                    (NN h))))))))
      (: ;)
      (NP
        (NP
          (LST (-LRB- -LRB-) (LS B) (-RRB- -RRB-))
          (NN RT–PCR))
        (PP (IN after)
          (NP
            (NP (NN treatment))
            (PP (IN of)
              (NP
                (NP (NN LAMA-84))
                (CC and)
                (NP (NN U-937))))
            (PP (IN with)
              (NP
                (NP (CD 3) (JJ µM) (NN AzadC))
                (PP (IN for)
                  (NP
                    (QP (CD 24) (, ,) (CD 48)
                      (CC and)
                      (CD 72))
                    (NN h))))))))
      (. .))))

(
  (S
    (NP
      (NP (NN Table) (CD 1))
      (: :)
      (NP
        (NP (NN Sequencing))
        (PP (IN of)
          (NP (JJ bisulfite-treated) (NN DNA)))
        (PP (IN from)
          (NP (JJ hematopoietic) (NNS cells)))))))

